1
|
Hench J, Hultschig C, Brugger J, Mariani L, Guzman R, Soleman J, Leu S, Benton M, Stec IM, Hench IB, Hoffmann P, Harter P, Weber KJ, Albers A, Thomas C, Hasselblatt M, Schüller U, Restelli L, Capper D, Hewer E, Diebold J, Kolenc D, Schneider UC, Rushing E, Della Monica R, Chiariotti L, Sill M, Schrimpf D, von Deimling A, Sahm F, Kölsche C, Tolnay M, Frank S. EpiDiP/NanoDiP: a versatile unsupervised machine learning edge computing platform for epigenomic tumour diagnostics. Acta Neuropathol Commun 2024; 12:51. [PMID: 38576030 PMCID: PMC10993614 DOI: 10.1186/s40478-024-01759-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/25/2023] [Accepted: 03/11/2024] [Indexed: 04/06/2024] Open
Abstract
DNA methylation analysis based on supervised machine learning algorithms with static reference data, allowing diagnostic tumour typing with unprecedented precision, has quickly become a new standard of care. Whereas genome-wide diagnostic methylation profiling is mostly performed on microarrays, an increasing number of institutions additionally employ nanopore sequencing as a faster alternative. In addition, methylation-specific parallel sequencing can generate methylation and genomic copy number data. Given these diverse approaches to methylation profiling, to date, there is no single tool that allows (1) classification and interpretation of microarray, nanopore and parallel sequencing data, (2) direct control of nanopore sequencers, and (3) the integration of microarray-based methylation reference data. Furthermore, no software capable of entirely running in routine diagnostic laboratory environments lacking high-performance computing and network infrastructure exists. To overcome these shortcomings, we present EpiDiP/NanoDiP as an open-source DNA methylation and copy number profiling suite, which has been benchmarked against an established supervised machine learning approach using in-house routine diagnostics data obtained between 2019 and 2021. Running locally on portable, cost- and energy-saving system-on-chip as well as gpGPU-augmented edge computing devices, NanoDiP works in offline mode, ensuring data privacy. It does not require the rigid training data annotation of supervised approaches. Furthermore, NanoDiP is the core of our public, free-of-charge EpiDiP web service which enables comparative methylation data analysis against an extensive reference data collection. We envision this versatile platform as a useful resource not only for neuropathologists and surgical pathologists but also for the tumour epigenetics research community. In daily diagnostic routine, analysis of native, unfixed biopsies by NanoDiP delivers molecular tumour classification in an intraoperative time frame.
Collapse
Affiliation(s)
- Jürgen Hench
- Institut für Medizinische Genetik und Pathologie, Universitätsspital Basel, Schönbeinstr. 40, 4031, Basel, Switzerland.
| | - Claus Hultschig
- Institut für Medizinische Genetik und Pathologie, Universitätsspital Basel, Schönbeinstr. 40, 4031, Basel, Switzerland
| | - Jon Brugger
- Institut für Medizinische Genetik und Pathologie, Universitätsspital Basel, Schönbeinstr. 40, 4031, Basel, Switzerland
| | - Luigi Mariani
- Klinik für Neurochirurgie, Universitätsspital Basel, Spitalstrasse 21, 4031, Basel, Switzerland
| | - Raphael Guzman
- Klinik für Neurochirurgie, Universitätsspital Basel, Spitalstrasse 21, 4031, Basel, Switzerland
| | - Jehuda Soleman
- Klinik für Neurochirurgie, Universitätsspital Basel, Spitalstrasse 21, 4031, Basel, Switzerland
| | - Severina Leu
- Klinik für Neurochirurgie, Universitätsspital Basel, Spitalstrasse 21, 4031, Basel, Switzerland
| | - Miles Benton
- Human Genomics, Institute of Environmental Science and Research (ESR), 5022, Porirua, Wellington, New Zealand
| | - Irenäus Maria Stec
- Institut für Medizinische Genetik und Pathologie, Universitätsspital Basel, Schönbeinstr. 40, 4031, Basel, Switzerland
| | - Ivana Bratic Hench
- Institut für Medizinische Genetik und Pathologie, Universitätsspital Basel, Schönbeinstr. 40, 4031, Basel, Switzerland
| | - Per Hoffmann
- Life&Brain GmbH, Venusberg-Campus 1, Gebäude 76, 53127, Bonn, Germany
| | - Patrick Harter
- Institute of Neuropathology, Center for Neuropathology and Prion Research, Feodor- Lynen-Str. 23, 81377, München, Germany
| | - Katharina J Weber
- Neurological Institute (Edinger Institute), University Hospital, Heinrich-Hoffmann- Straße 7, 60528, Frankfurt am Main, Germany
- German Cancer Consortium (DKTK), Partner Site Frankfurt, German Cancer Research Center (DKFZ), Heidelberg, Germany
- Frankfurt Cancer Institute (FCI), Frankfurt am Main, Germany
| | - Anne Albers
- Institute of Neuropathology, University Hospital Münster, Pottkamp 2, 48149, Münster, Germany
| | - Christian Thomas
- Institute of Neuropathology, University Hospital Münster, Pottkamp 2, 48149, Münster, Germany
| | - Martin Hasselblatt
- Institute of Neuropathology, University Hospital Münster, Pottkamp 2, 48149, Münster, Germany
| | - Ulrich Schüller
- Forschungsinstitut Kinderkrebszentrum, Martinistrasse 52, 20251, Hamburg, Germany
- Department of Pediatric Hematology and Oncology, University Hospital Hamburg- Eppendorf, Hamburg, Germany
- Institute of Neuropathology, University Hospital Hamburg-Eppendorf, Hamburg, Germany
- Department of Neuropathology, Department of Neuropathology, Charité- Universitätsmedizin Berlin, Charitéplatz 1, 10117, Berlin, Germany
| | - Lisa Restelli
- Institut für Medizinische Genetik und Pathologie, Universitätsspital Basel, Schönbeinstr. 40, 4031, Basel, Switzerland
| | - David Capper
- , 15. Luzerner Kantonsspital, Pathologie, Haus 27, 6000, Spitalstrasse, Luzern 16, Switzerland
| | - Ekkehard Hewer
- Institut universitaire de pathologie, Lausanne University Hospital (CHUV), University of Lausanne, Rue du Bugnon 25, 1011, Lausanne, Switzerland
| | - Joachim Diebold
- , 15. Luzerner Kantonsspital, Pathologie, Haus 27, 6000, Spitalstrasse, Luzern 16, Switzerland
| | - Danijela Kolenc
- , 15. Luzerner Kantonsspital, Pathologie, Haus 27, 6000, Spitalstrasse, Luzern 16, Switzerland
| | - Ulf C Schneider
- Klinik für Neurochirurgie, Luzerner Kantonsspital, Haus 31, 6000, 16, Spitalstrasse, Luzern, Switzerland
| | - Elisabeth Rushing
- , 15. Luzerner Kantonsspital, Pathologie, Haus 27, 6000, Spitalstrasse, Luzern 16, Switzerland
- Medica Pathologie Zentrum Zürich, Hottingerstrasse 9 / 11, 8032, Zürich, Switzerland
| | - Rosa Della Monica
- CEINGE-Biotecnologie Avanzate, Via Gaetano Salvatore, 486 - 80145, Napoli, Italy
| | - Lorenzo Chiariotti
- CEINGE-Biotecnologie Avanzate, Via Gaetano Salvatore, 486 - 80145, Napoli, Italy
| | - Martin Sill
- Hopp Children's Cancer Center Heidelberg (KiTZ), Heidelberg, Germany
- Division of Pediatric Neurooncology, German Consortium for Translational Cancer Research (DKTK), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany
| | - Daniel Schrimpf
- Department of Neuropathology, Institute of Neuropathology, University Hospital Heidelberg, Im Neuenheimer Feld 280, 69120, Heidelberg, Germany
| | - Andreas von Deimling
- Department of Neuropathology, Institute of Neuropathology, University Hospital Heidelberg, Im Neuenheimer Feld 280, 69120, Heidelberg, Germany
| | - Felix Sahm
- Department of Neuropathology, Institute of Neuropathology, University Hospital Heidelberg, Im Neuenheimer Feld 280, 69120, Heidelberg, Germany
- CCU Neuropathology, German Consortium for Translational Cancer Research (DKTK), Im Neuenheimer Feld 280, 69120, Heidelberg, Germany
- , 23. DKFZ, Im Neuenheimer Feld 280, 69120, Heidelberg, Germany
| | - Christian Kölsche
- Pathologisches Institut der LMU, Thalkirchner Str. 36, 80337, München, Germany
| | - Markus Tolnay
- Institut für Medizinische Genetik und Pathologie, Universitätsspital Basel, Schönbeinstr. 40, 4031, Basel, Switzerland
| | - Stephan Frank
- Institut für Medizinische Genetik und Pathologie, Universitätsspital Basel, Schönbeinstr. 40, 4031, Basel, Switzerland.
| |
Collapse
|
2
|
Frei AL, Oberson R, Baumann E, Perren A, Grobholz R, Lugli A, Dawson H, Abbet C, Lertxundi I, Reinhard S, Mookhoek A, Feichtinger J, Sarro R, Gadient G, Dommann-Scherrer C, Barizzi J, Berezowska S, Glatz K, Dertinger S, Banz Y, Schoenegg R, Rubbia-Brandt L, Fleischmann A, Saile G, Mainil-Varlet P, Biral R, Giudici L, Soltermann A, Chaubert AB, Stadlmann S, Diebold J, Egervari K, Bénière C, Saro F, Janowczyk A, Zlobec I. Pathologist Computer-Aided Diagnostic Scoring of Tumor Cell Fraction: A Swiss National Study. Mod Pathol 2023; 36:100335. [PMID: 37742926 DOI: 10.1016/j.modpat.2023.100335] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2023] [Revised: 08/25/2023] [Accepted: 09/15/2023] [Indexed: 09/26/2023]
Abstract
Tumor cell fraction (TCF) estimation is a common clinical task with well-established large interobserver variability. It thus provides an ideal test bed to evaluate potential impacts of employing a tumor cell fraction computer-aided diagnostic (TCFCAD) tool to support pathologists' evaluation. During a National Slide Seminar event, pathologists (n = 69) were asked to visually estimate TCF in 10 regions of interest (ROIs) from hematoxylin and eosin colorectal cancer images intentionally curated for diverse tissue compositions, cellularity, and stain intensities. Next, they re-evaluated the same ROIs while being provided a TCFCAD-created overlay highlighting predicted tumor vs nontumor cells, together with the corresponding TCF percentage. Participants also reported confidence levels in their assessments using a 5-tier scale, indicating no confidence to high confidence, respectively. The TCF ground truth (GT) was defined by manual cell-counting by experts. When assisted, interobserver variability significantly decreased, showing estimates converging to the GT. This improvement remained even when TCFCAD predictions deviated slightly from the GT. The standard deviation (SD) of the estimated TCF to the GT across ROIs was 9.9% vs 5.8% with TCFCAD (P < .0001). The intraclass correlation coefficient increased from 0.8 to 0.93 (95% CI, 0.65-0.93 vs 0.86-0.98), and pathologists stated feeling more confident when aided (3.67 ± 0.81 vs 4.17 ± 0.82 with the computer-aided diagnostic [CAD] tool). TCFCAD estimation support demonstrated improved scoring accuracy, interpathologist agreement, and scoring confidence. Interestingly, pathologists also expressed more willingness to use such a CAD tool at the end of the survey, highlighting the importance of training/education to increase adoption of CAD systems.
Collapse
Affiliation(s)
- Ana Leni Frei
- Institute for Tissue Medicine and Pathology, University of Bern, Bern, Switzerland.
| | - Raphaël Oberson
- Institute for Tissue Medicine and Pathology, University of Bern, Bern, Switzerland
| | - Elias Baumann
- Institute for Tissue Medicine and Pathology, University of Bern, Bern, Switzerland
| | - Aurel Perren
- Institute for Tissue Medicine and Pathology, University of Bern, Bern, Switzerland
| | - Rainer Grobholz
- Medical Faculty University of Zurich, Institute of Pathology, Cantonal Hospital Aarau, Aarau, Switzerland
| | - Alessandro Lugli
- Institute for Tissue Medicine and Pathology, University of Bern, Bern, Switzerland
| | - Heather Dawson
- Institute for Tissue Medicine and Pathology, University of Bern, Bern, Switzerland
| | - Christian Abbet
- Signal Processing Laboratory 5, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
| | - Ibai Lertxundi
- Institute for Tissue Medicine and Pathology, University of Bern, Bern, Switzerland
| | - Stefan Reinhard
- Institute for Tissue Medicine and Pathology, University of Bern, Bern, Switzerland
| | - Aart Mookhoek
- Institute for Tissue Medicine and Pathology, University of Bern, Bern, Switzerland
| | | | - Rossella Sarro
- Istituto Cantonale di Patologia, Ente ospedaliero cantonale (EOC), Locarno, Switzerland
| | | | | | - Jessica Barizzi
- Istituto Cantonale di Patologia, Ente ospedaliero cantonale (EOC), Locarno, Switzerland
| | - Sabina Berezowska
- Institute of Pathology, Lausanne University Hospital, Lausanne, Switzerland
| | - Katharina Glatz
- Institut of Pathology, University Hospital Basel, Basel, Switzerland
| | - Susanne Dertinger
- Institute of Pathology, Landeskrankenhaus Feldkirch, Feldkirch, Austria
| | - Yara Banz
- Institute for Tissue Medicine and Pathology, University of Bern, Bern, Switzerland
| | - Rene Schoenegg
- Institute of Pathology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
| | - Laura Rubbia-Brandt
- Department of Pathology and Immunology, Geneva University Hospital, Genève, Switzerland
| | - Achim Fleischmann
- Institute of Pathology, Cantonal Hospital Thurgau, Münsterlingen, Switzerland
| | | | | | | | - Luca Giudici
- Istituto Cantonale di Patologia, Ente ospedaliero cantonale (EOC), Locarno, Switzerland
| | | | - Audrey Baur Chaubert
- FMH Pathology, Pathology Department of SYNLAB Switzerland SA, Lausanne, Switzerland
| | - Sylvia Stadlmann
- Institute of Pathology, Cantonal Hospital Baden, Baden, Switzerland
| | - Joachim Diebold
- Institute of Pathology, Cantonal Hospital Luzern, Luzern, Switzerland
| | - Kristof Egervari
- Department of Pathology and Immunology, Geneva University Hospital, Genève, Switzerland
| | | | - Francesca Saro
- Institute of Pathology and Molecular Pathology, University Hospital Zürich, Zürich, Switzerland
| | - Andrew Janowczyk
- Department of Biomedical Engineering, Emory University, Atlanta, Georgia; Department of Oncology, Division of Precision Oncology, University Hospital of Geneva, Geneva, Switzerland; Department of Clinical Pathology, Division of Clinical Pathology, University Hospital of Geneva, Geneva, Switzerland
| | - Inti Zlobec
- Institute for Tissue Medicine and Pathology, University of Bern, Bern, Switzerland.
| |
Collapse
|
3
|
Nevzati E, Poletti N, Spiessberger A, Bäbler S, Studer G, Riklin C, Diebold J, Chatain GP, Finn M, Witt JP, Moser M, Mariani L. Establishing the Swiss Spinal Tumor Registry (Swiss-STR): a prospective observation of surgical treatment patterns and long-term outcomes in patients with primary and metastatic spinal tumors. Front Surg 2023; 10:1222595. [PMID: 37576924 PMCID: PMC10416635 DOI: 10.3389/fsurg.2023.1222595] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2023] [Accepted: 07/12/2023] [Indexed: 08/15/2023] Open
Abstract
Background Tumors of the vertebral column consist of primary spinal tumors and malignancies metastasizing to the spine. Although primary spine tumors are rare, metastases to the spine have gradually increased over past decades because of aging populations and improved survival for various cancer subtypes achieved by advances in cancer therapy. Metastases to the vertebral column occur in up to 70% of cancer patients, with 10% of patients demonstrating epidural spinal cord compression. Therefore, many cancer patients may face spinal surgical intervention during their chronic illness; such interventions range from simple cement augmentation over decompression of neural elements to extended instrumentation or spinal reconstruction. However, precise surgical treatment guidelines do not exist, likely due to the lack of robust, long-term clinical outcomes data and the overall heterogeneous nature of spinal tumors. Objectives of launching the Swiss Spinal Tumor Registry (Swiss-STR) are to collect and analyze high-quality, prospective, observational data on treatment patterns, clinical outcomes, and health-related quality of life (HRQoL) in adult patients undergoing spinal tumor surgery. This narrative review discusses our rationale and process of establishing this spinal cancer registry. Methods A REDCap-based registry was created for the standardized collection of clinical, radiographic, surgical, histological, radio-oncologial and oncological variables, as well as patient-reported outcome measures (PROMs). Discussion We propose that the Swiss-STR will inform on the effectiveness of current practices in spinal oncology and their impact on patient outcomes. Furthermore, the registry will enable better categorization of the various clinical presentations of spinal tumors, thereby facilitating treatment recommendations, defining the socio-economic burden on the healthcare system, and improving the quality of care. In cases of rare tumors, the multi-center data pooling will fill significant data gaps to yield better understanding of these entities. Finally, our two-step approach first implements a high-quality registry with efficient electronic data capture strategies across hospital sites in Switzerland, and second follows with potential to expand internationally, thus fostering future international scientific collaboration to further push the envelope in cancer research.
Collapse
Affiliation(s)
- Edin Nevzati
- Department of Neurosurgery, Cantonal Hospital of Lucerne, Lucerne, Switzerland
- Department of Spine Surgery, Cantonal Hospital of Lucerne, Lucerne, Switzerland
| | - Nicolas Poletti
- Department of Neurosurgery, University Hospital of Basel, Basel, Switzerland
| | | | - Sabrina Bäbler
- Department of Neurosurgery, Cantonal Hospital of Lucerne, Lucerne, Switzerland
- Department of Spine Surgery, Cantonal Hospital of Lucerne, Lucerne, Switzerland
| | - Gabriela Studer
- Department of Radiation-Oncology, Cantonal Hospital of Lucerne, Lucerne, Switzerland
| | - Christian Riklin
- Department of Oncology, Cantonal Hospital of Lucerne, Lucerne, Switzerland
| | - Joachim Diebold
- Department of Pathology, Cantonal Hospital of Lucerne, Lucerne, Switzerland
| | - Grégoire P. Chatain
- Department of Neurosurgery, University of Colorado Anschutz Medical Campus School of Medicine, Auror, CO, United States
| | - Michael Finn
- Department of Neurosurgery, University of Colorado Anschutz Medical Campus School of Medicine, Auror, CO, United States
| | - Jens-Peter Witt
- Department of Neurosurgery, University of Colorado Anschutz Medical Campus School of Medicine, Auror, CO, United States
| | - Manuel Moser
- Department of Neurosurgery, Cantonal Hospital of Lucerne, Lucerne, Switzerland
- Department of Spine Surgery, Cantonal Hospital of Lucerne, Lucerne, Switzerland
| | - Luigi Mariani
- Department of Neurosurgery, University Hospital of Basel, Basel, Switzerland
| |
Collapse
|
4
|
Allmann V, Dyntar D, Lehnick D, Dressler M, Zeidler K, Niederberger P, Godau J, Diebold J, Gautschi O. Overall survival and role of programmed death ligand 1 expression in patients with metastatic non-small-cell lung cancer and immunotherapy: an observational study from central Switzerland. Swiss Med Wkly 2023; 153:40039. [PMID: 36787492 DOI: 10.57187/smw.2023.40039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/11/2023] Open
Abstract
BACKGROUND In clinical trials, therapy with immune checkpoint inhibitors has improved the survival of patients with metastatic non-small-cell lung cancer (NSCLC). These trials were important for drug approval and for defining new treatment standards but the effect of checkpoint inhibitors in patients treated outside of clinical trials is not well known. The goal of this study was to assess the effect of immunotherapy on the overall survival of patients with metastatic NSCLC in the region of central Switzerland. MATERIALS AND METHODS The study included 274 patients with histologically confirmed metastatic (stage IV) NSCLC in central Switzerland in the years 2015 to 2018. Patients with NSCLC and actionable driver mutations were excluded. Patients with checkpoint inhibitor treatment (immuno-oncology [IO] group, n = 122) were compared with patients without checkpoint inhibitor treatment (no-IO group, n = 152). Baseline demographics, disease characteristics and therapies applied were collected retrospectively. The primary endpoint was median overall survival calculated either from diagnosis or from the start of checkpoint inhibitor therapy to death or data cut-off (21 July 2021). We used the Kaplan-Meier method and an adjusted Cox proportional-hazards regression model. The expression of programmed-death ligand 1 (PD-L1) on tumour cells was used for exploratory analysis. RESULTS Patients had a median age of 68.4 years, most were male (61.7%) and more than half were current or former smokers (65%). A test for PD-L1 expression was available for 55.8% of the tumours. Patients in the IO group were younger than patients in the no-IO group. Among the 122 patients in the IO group, the median overall survival was 15 months (95% confidence interval [CI] 12-20). In the no-IO group, the median overall survival was 4 months (95% CI 3-7) with chemotherapy and 2 months (95% CI 1-2) with best supportive care. Patients with high (≥50%) PD-L1 expression and checkpoint inhibitor therapy had a slightly longer overall survival than patients with low PD-L1 and checkpoint inhibitor therapy. CONCLUSION These results suggest that treatment with checkpoint inhibitors improves overall survival in patients with metastatic NSCLC and that PD-L1 expression could have a predictive value in patients treated outside of clinical trials. Further studies are needed to study the magnitude of the benefit of checkpoint inhibitors according to molecular NSCLC subtype.
Collapse
Affiliation(s)
| | - Daniela Dyntar
- Cancer Registry of Central Switzerland, Cantonal Hospital Lucerne, Switzerland
| | - Dirk Lehnick
- Biostatistics and Methodology, Department of Health Sciences and Medicine, University of Lucerne, Switzerland
| | - Marco Dressler
- Department of Medical Oncology, Clinic Hirslanden St Anna, Lucerne, Switzerland
| | - Kristin Zeidler
- Department of Medical Oncology, Cantonal Hospital Nidwalden, Stans, Switzerland
| | | | - Jeanne Godau
- Department of Medical Oncology, Cantonal Hospital Uri, Altdorf, Switzerland
| | - Joachim Diebold
- Institute of Pathology, Cantonal Hospital Lucerne, Switzerland
| | - Oliver Gautschi
- University of Bern and Cantonal Hospital of Lucerne, Switzerland
| |
Collapse
|
5
|
Quintavalle C, Meyer‐Schaller N, Roessler S, Calabrese D, Marone R, Riedl T, Picco‐Rey S, Panagiotou OA, Uzun S, Piscuoglio S, Boldanova T, Bian CB, Semela D, Jochum W, Cathomas G, Mertz KD, Diebold J, Mazzucchelli L, Koelzer VH, Weber A, Decaens T, Terracciano LM, Heikenwalder M, Hoshida Y, Andersen JB, Thorgeirsson SS, Matter MS. miR-579-3p Controls Hepatocellular Carcinoma Formation by Regulating the Phosphoinositide 3-Kinase-Protein Kinase B Pathway in Chronically Inflamed Liver. Hepatol Commun 2022; 6:1467-1481. [PMID: 35132819 PMCID: PMC9134798 DOI: 10.1002/hep4.1894] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/18/2021] [Revised: 12/06/2021] [Accepted: 12/16/2021] [Indexed: 12/02/2022] Open
Abstract
Chronic liver inflammation causes continuous liver damage with progressive liver fibrosis and cirrhosis, which may eventually lead to hepatocellular carcinoma (HCC). Whereas the 10-year incidence for HCC in patients with cirrhosis is approximately 20%, many of these patients remain tumor free for their entire lives. Clarifying the mechanisms that define the various outcomes of chronic liver inflammation is a key aspect in HCC research. In addition to a wide variety of contributing factors, microRNAs (miRNAs) have also been shown to be engaged in promoting liver cancer. Therefore, we wanted to characterize miRNAs that are involved in the development of HCC, and we designed a longitudinal study with formalin-fixed and paraffin-embedded liver biopsy samples from several pathology institutes from Switzerland. We examined the miRNA expression by nCounterNanostring technology in matched nontumoral liver tissue from patients developing HCC (n = 23) before and after HCC formation in the same patient. Patients with cirrhosis (n = 26) remaining tumor free within a similar time frame served as a control cohort. Comparison of the two cohorts revealed that liver tissue from patients developing HCC displayed a down-regulation of miR-579-3p as an early step in HCC development, which was further confirmed in a validation cohort. Correlation with messenger RNA expression profiles further revealed that miR-579-3p directly attenuated phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) expression and consequently protein kinase B (AKT) and phosphorylated AKT. In vitro experiments and the use of clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 technology confirmed that miR-579-3p controlled cell proliferation and cell migration of liver cancer cell lines. Conclusion: Liver tissues from patients developing HCC revealed changes in miRNA expression. miR-579-3p was identified as a novel tumor suppressor regulating phosphoinositide 3-kinase-AKT signaling at the early stages of HCC development.
Collapse
Affiliation(s)
- Cristina Quintavalle
- Institute of PathologyUniversity Hospital of BaselUniversity of BaselBaselSwitzerland
| | | | | | - Diego Calabrese
- Department of BiomedicineUniversity of BaselBaselSwitzerland
- Division of Hepatology and GastroenterologyUniversity Hospital of BaselBaselSwitzerland
| | - Romina Marone
- Department of BiomedicineUniversity Hospital of Basel, University of BaselBaselSwitzerland
| | - Tobias Riedl
- Division of Chronic Inflammation and CancerGerman Cancer Research CenterHeidelbergGermany
| | - Silvia Picco‐Rey
- Institute of PathologyUniversity Hospital of BaselUniversity of BaselBaselSwitzerland
| | - Orestis A. Panagiotou
- Department of Health Services, Policy and PracticeBrown University School of Public HealthProvidenceRIUSA
| | - Sarp Uzun
- Institute of PathologyUniversity Hospital of BaselUniversity of BaselBaselSwitzerland
| | - Salvatore Piscuoglio
- Institute of PathologyUniversity Hospital of BaselUniversity of BaselBaselSwitzerland
| | - Tuyana Boldanova
- Department of BiomedicineUniversity of BaselBaselSwitzerland
- Division of Hepatology and GastroenterologyUniversity Hospital of BaselBaselSwitzerland
| | - Chaoran B. Bian
- Department of Genetics and Genomic SciencesGraduate School of Biomedical SciencesIcahn School of Medicine at Mount SinaiNew YorkNYUSA
| | - David Semela
- Division of GastroenterologyKantonsspital St. GallenSt. GallenSwitzerland
| | - Wolfram Jochum
- Institute of PathologyKantonsspital St. GallenSt. GallenSwitzerland
| | - Gieri Cathomas
- Institute of PathologyKantonsspital BasellandLiestalSwitzerland
| | | | - Joachim Diebold
- Institute of PathologyLuzerner KantonsspitalLucerneSwitzerland
| | | | - Viktor H. Koelzer
- Department of Pathology and Molecular PathologyUniversity and University Hospital ZurichZurichSwitzerland
| | - Achim Weber
- Department of Pathology and Molecular PathologyUniversity and University Hospital ZurichZurichSwitzerland
| | - Thomas Decaens
- Institute for Advanced BiosciencesINSERM U1209/CNRS UMR 5309/Université Grenoble‐AlpesGrenobleFrance
- Université Grenoble AlpesGrenobleFrance
- Clinique Universitaire d'Hépato‐gastroentérologie, Pôle DigiduneCentre Hospitalier UniversitaireGrenobleFrance
| | - Luigi M. Terracciano
- Institute of PathologyUniversity Hospital of BaselUniversity of BaselBaselSwitzerland
| | - Mathias Heikenwalder
- Division of Chronic Inflammation and CancerGerman Cancer Research CenterHeidelbergGermany
| | - Yujin Hoshida
- Liver Tumor ProgramSimmons Comprehensive Cancer CenterDivision of Digestive and Liver DiseasesUniversity of Texas Southwestern Medical CenterDallasTXUSA
| | - Jesper B. Andersen
- Biotech Research and Innovation CenterDepartment of Health and Medical SciencesUniversity of CopenhagenCopenhagenDenmark
| | - Snorri S. Thorgeirsson
- Laboratory of Experimental CarcinogenesisCenter for Cancer ResearchNational Cancer Institute‐National Institutes of HealthBethesdaMDUSA
| | - Matthias S. Matter
- Institute of PathologyUniversity Hospital of BaselUniversity of BaselBaselSwitzerland
| |
Collapse
|
6
|
Allmann V, Gautschi O, Lehnick D, Dyntar D, Schwegler C, Dressler M, Godau J, Niederberger P, Zeidler K, Diebold J. 46P Prognostic impact of immune checkpoint inhibition in patients with metastatic non-small cell lung cancer (NSCLC): Real-world study in central Switzerland. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.02.055] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
7
|
Taha-Mehlitz S, Mongelli F, Sykora M, Scheiwiller A, Diebold J, Metzger J, Gass JM. Routine histopathologic examination of the resected specimen after laparoscopic sleeve gastrectomy - what can be expected? Acta Chir Belg 2021; 121:380-385. [PMID: 32644013 DOI: 10.1080/00015458.2020.1794335] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BACKGROUND Laparoscopic Sleeve Gastrectomy (LSG) is nowadays an established bariatric procedure. Although preoperative gastroscopy is recommended to rule out severe pathologies, there is little evidence about the role of routine histopathologic examination of resected specimens. We sought to identify the prevalence of histopathological relevant findings in patients undergoing LSG and to evaluate their impact in clinical practice. METHODS A retrospective analysis on a prospectively collected dataset on patients undergoing LSG between August 2009 and May 2018 in two bariatric centers was performed. Demographic and clinical data and histopathological results were analyzed. RESULTS Sixhundred-thrirteen patients were identified, mean age was 43.1 years (14-75), average body mass index was 44.8 kg/m2 (34.4-73.9). Histopathology revealed abnormal findings in 47.97% of the patients, most common pathology was chronic non-active or minimally to moderate active gastritis (n = 202;32.95%). Among others, Helicobacter-associated gastritis (n = 33;5.38%), intestinal metaplasia (n = 13;2.12%), micronodular enterochromaffine-like cell hyperplasia (n = 2; 0.33%) and gastrointestinal stromal tumors (n = 6; 0.98%) were present. No malignancies were found. Histopathological results required a change in the postoperative management in 48 patients (7.83%). The costs of histopathological assessment ranged between 0.77% and 2.55% of per-case payment. CONCLUSION A wide range of histopathological findings occur in specimens after LSG, requiring a relevant number of patients additional therapies or surveillance. Therefore, routine histopathological examination after LSG is recommendable.
Collapse
Affiliation(s)
| | - Francesco Mongelli
- Department of General Surgery, Cantonal Hospital Lucerne, Spitalstrasse, Switzerland
| | - Martin Sykora
- Department of General Surgery, Cantonal Hospital of Nidwalden, Postfach, Switzerland
| | - Andreas Scheiwiller
- Department of General Surgery, Cantonal Hospital Lucerne, Spitalstrasse, Switzerland
| | - Joachim Diebold
- Department of Pathology, Cantonal Hospital Lucerne, Spitalstrasse, Switzerland
| | - Jürg Metzger
- Department of General Surgery, Cantonal Hospital Lucerne, Spitalstrasse, Switzerland
| | - Jörn-Markus Gass
- Department of General Surgery, Cantonal Hospital Lucerne, Spitalstrasse, Switzerland
| |
Collapse
|
8
|
Gautschi O, Diebold J. Intracranial Activity of Osimertinib Plus Capmatinib in a Patient With EGFR and MET-Driven Lung Cancer: Case Report. JTO Clin Res Rep 2021; 2:100162. [PMID: 34590012 PMCID: PMC8474278 DOI: 10.1016/j.jtocrr.2021.100162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2021] [Revised: 02/23/2021] [Accepted: 02/26/2021] [Indexed: 11/25/2022] Open
Abstract
We previously published in the Journal of Thoracic Oncology the case of a patient with EGFR and MET-driven lung cancer and extracranial response to capmatinib and osimertinib. Here, we report on a second patient treated with the same combination, revealing complete and durable intracranial response. Adding capmatinib to osimertinib seems to be an effective salvage therapy for patients with EGFR-mutant lung cancer and acquired MET amplification.
Collapse
Affiliation(s)
- Oliver Gautschi
- Cantonal Hospital Lucerne, Cancer Center, Lucerne, Switzerland
| | - Joachim Diebold
- Cantonal Hospital Lucerne, Cancer Center, Lucerne, Switzerland
| |
Collapse
|
9
|
Van Treeck BJ, Thangaiah JJ, Torres-Mora J, Stevens TM, Rothermundt C, Fassan M, Loupakis F, Diebold J, Hornick JL, Halling KC, Folpe AL. NUTM1-rearranged colorectal sarcoma: a clinicopathologically and genetically distinctive malignant neoplasm with a poor prognosis. Mod Pathol 2021; 34:1547-1557. [PMID: 33714983 DOI: 10.1038/s41379-021-00792-z] [Citation(s) in RCA: 21] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2021] [Revised: 02/25/2021] [Accepted: 02/25/2021] [Indexed: 01/10/2023]
Abstract
NUTM1 gene rearrangements were originally identified in NUT carcinoma. Recently, NUTM1 has been discovered to rearrange with a variety of gene partners in malignancies of diverse location and type. Only one NUTM1-rearranged tumor occurring in the colon has been reported. Herein we report five such tumors. The five tumors occurred in four females and one male, ranging from 38 to 67 years of age (median 51 years). The masses occurred in the colon (cecum, descending, sigmoid) and ileocecal valve region, measuring 2.5-20 cm in size (median 7 cm). Four patients had metastases at presentation (liver, n = 4; lymph nodes, n = 3). Histologically, the lesions arose in the submucosa, infiltrating into the mucosa and muscularis propria, and grew in fibrosarcoma-like fascicles and sheets of epithelioid or rhabdoid cells, with foci of hyalinized to vaguely osteoid-like matrix. The tumors were composed of relatively monomorphic, spindled to epithelioid cells with focal rhabdoid morphology, hyperchromatic nuclei, and small nucleoli. Mitotic activity was usually low (range 1-14/10 HPF; median 5/10 HPF); necrosis was present in two cases. Variable keratin expression and uniform nuclear NUT expression was present; KIT/DOG1 were negative and SMARCB1/SMARCA4 were retained. Next-generation sequencing identified MXD4-NUTM1 rearrangement in all cases (breakpoints: MXD4 exon 5, NUTM1 exons 2 or 3). Follow-up showed one of the four patients who presented with metastases to be dead of disease at 30 months; the other three patients were alive with metastatic disease. The final patient is disease-free, 5 months after diagnosis. NUTM1-rearranged colorectal sarcomas have characteristic morphologic, immunohistochemical, and molecular genetic features, suggesting that they represent a distinct entity within the family of NUTM1-rearranged neoplasia. A NUTM1-rearranged tumor should be considered for any difficult-to-classify submucosal spindle cell neoplasm of the gastrointestinal tract, in particular keratin-positive tumors showing an unusual combination of fibrosarcomatous, epithelioid to rhabdoid and hyalinized morphologies. Recognition of MXD4-NUTM1 rearranged sarcomas may be therapeutically important, even though best treatment is currently elusive/unknown.
Collapse
Affiliation(s)
| | | | - Jorge Torres-Mora
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
| | - Todd M Stevens
- Division of Anatomic Pathology, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Christian Rothermundt
- Department of Oncology and Hematology, St. Gallen Cantonal Hospital, St. Gallen, Switzerland
| | - Matteo Fassan
- Department of Medicine, Surgical Pathology Unit, University of Padua, Padua, Italy
| | - Fotios Loupakis
- Unit of Medical Oncology 1, Department of Oncology, Veneto Institute of Oncology IRCCS, Padua, Italy
| | - Joachim Diebold
- Department of Pathology, Cantonal Hospital, Lucerne, Switzerland
| | - Jason L Hornick
- Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | - Kevin C Halling
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA
| | - Andrew L Folpe
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.
| |
Collapse
|
10
|
Vela V, Juskevicius D, Prince SS, Cathomas G, Dertinger S, Diebold J, Bubendorf L, Horcic M, Singer G, Zettl A, Dirnhofer S, Tzankov A, Menter T. Deciphering the genetic landscape of pulmonary lymphomas. Mod Pathol 2021; 34:371-379. [PMID: 32855441 DOI: 10.1038/s41379-020-00660-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2020] [Revised: 08/07/2020] [Accepted: 08/07/2020] [Indexed: 12/17/2022]
Abstract
Pulmonary lymphoid malignancies comprise various entities, 80% of them are pulmonary marginal zone B-cell lymphomas (PMZL). So far, little is known about point mutations in primary pulmonary lymphomas. We characterized the genetic landscape of primary pulmonary lymphomas using a customized high-throughput sequencing gene panel covering 146 genes. Our cohort consisted of 28 PMZL, 14 primary diffuse large B-cell lymphomas (DLBCL) of the lung, 7 lymphomatoid granulomatoses (LyG), 5 mature small B-cell lymphomas and 16 cases of reactive lymphoid lesions. Mutations were detected in 22/28 evaluable PMZL (median 2 mutation/case); 14/14 DLBCL (median 3 mutations/case) and 4/7 LyG (1 mutation/case). PMZL showed higher prevalence for mutations in chromatin modifier-encoding genes (44% of mutant genes), while mutations in genes related to the NF-κB pathway were less common (24% of observed mutations). There was little overlap between mutations in PMZL and DLBCL. MALT1 rearrangements were more prevalent in PMZL than BCL10 aberrations, and both were absent in DLBCL. LyG were devoid of gene mutations associated with immune escape. The mutational landscape of PMZL differs from that of extranodal MZL of other locations and also from splenic MZL. Their landscape resembles more that of nodal MZL, which also show a predominance of mutations of chromatin modifiers. The different mutational composition of pulmonary DLBCL compared to PMZL suggests that the former probably do not present transformations. DLBCL bear more mutations/case and immune escape gene mutations compared to LyG, suggesting that EBV infection in LyG may substitute for mutations.
Collapse
Affiliation(s)
- Visar Vela
- Pathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland
| | - Darius Juskevicius
- Pathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland
| | - Spasenija Savic Prince
- Pathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland
| | - Gieri Cathomas
- Institute of Pathology, Cantonal Hospital Baselland, Liestal, Switzerland
| | | | - Joachim Diebold
- Institute of Pathology, Cantonal Hospital Lucerne, Lucerne, Switzerland
| | - Lukas Bubendorf
- Pathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland
| | - Milo Horcic
- Institute for Histologic und Cytologic Diagnostics AG, Aarau, Switzerland
| | - Gad Singer
- Institute of Pathology, Cantonal Hospital Baden, Baden, Switzerland
| | - Andreas Zettl
- Institute of Pathology, Viollier AG, Allschwil, Switzerland
| | - Stefan Dirnhofer
- Pathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland
| | - Alexandar Tzankov
- Pathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland.
| | - Thomas Menter
- Pathology, Institute of Medical Genetics and Pathology, University Hospital Basel, University of Basel, Basel, Switzerland
| |
Collapse
|
11
|
van Leeuwen RJH, Brunner S, Pojda J, Diebold J, Kestenholz P, Minervini F. Intrapulmonary solitary fibrous tumor with adenofibromatous pattern with features of pleomorphic high grade sarcoma-a case report and an overview of the differential diagnosis. Quant Imaging Med Surg 2021; 11:472-478. [PMID: 33392045 DOI: 10.21037/qims-20-598] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Affiliation(s)
| | - Stefanie Brunner
- Department of Surgery, Luzerner Kantonsspital, Lucerne, Switzerland
| | - Jan Pojda
- Department of Pathology, Luzerner Kantonsspital, Lucerne, Switzerland
| | - Joachim Diebold
- Department of Pathology, Luzerner Kantonsspital, Lucerne, Switzerland
| | - Peter Kestenholz
- Department of Thoracic Surgery, Luzerner Kantonsspital, Lucerne, Switzerland
| | - Fabrizio Minervini
- Department of Thoracic Surgery, Luzerner Kantonsspital, Lucerne, Switzerland
| |
Collapse
|
12
|
Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot AB, Mezquita L, Thai AA, Mascaux C, Couraud S, Veillon R, Van den Heuvel M, Neal J, Peled N, Früh M, Ng TL, Gounant V, Popat S, Diebold J, Sabari J, Zhu VW, Rothschild SI, Bironzo P, Martinez-Marti A, Curioni-Fontecedro A, Rosell R, Lattuca-Truc M, Wiesweg M, Besse B, Solomon B, Barlesi F, Schouten RD, Wakelee H, Camidge DR, Zalcman G, Novello S, Ou SI, Milia J, Gautschi O. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol 2020; 30:1321-1328. [PMID: 31125062 PMCID: PMC7389252 DOI: 10.1093/annonc/mdz167] [Citation(s) in RCA: 759] [Impact Index Per Article: 189.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Background Anti-PD1/PD-L1 directed immune checkpoint inhibitors (ICI) are widely used to treat patients with advanced non-small-cell lung cancer (NSCLC). The activity of ICI across NSCLC harboring oncogenic alterations is poorly characterized. The aim of our study was to address the efficacy of ICI in the context of oncogenic addiction. Patients and methods We conducted a retrospective study for patients receiving ICI monotherapy for advanced NSCLC with at least one oncogenic driver alteration. Anonymized data were evaluated for clinicopathologic characteristics and outcomes for ICI therapy: best response (RECIST 1.1), progression-free survival (PFS), and overall survival (OS) from ICI initiation. The primary end point was PFS under ICI. Secondary end points were best response (RECIST 1.1) and OS from ICI initiation. Results We studied 551 patients treated in 24 centers from 10 countries. The molecular alterations involved KRAS (n = 271), EGFR (n = 125), BRAF (n = 43), MET (n = 36), HER2 (n = 29), ALK (n = 23), RET (n = 16), ROS1 (n = 7), and multiple drivers (n = 1). Median age was 60 years, gender ratio was 1 : 1, never/former/current smokers were 28%/51%/21%, respectively, and the majority of tumors were adenocarcinoma. The objective response rate by driver alteration was: KRAS = 26%, BRAF = 24%, ROS1 = 17%, MET = 16%, EGFR = 12%, HER2 = 7%, RET = 6%, and ALK = 0%. In the entire cohort, median PFS was 2.8 months, OS 13.3 months, and the best response rate 19%. In a subgroup analysis, median PFS (in months) was 2.1 for EGFR, 3.2 for KRAS, 2.5 for ALK, 3.1 for BRAF, 2.5 for HER2, 2.1 for RET, and 3.4 for MET. In certain subgroups, PFS was positively associated with PD-L1 expression (KRAS, EGFR) and with smoking status (BRAF, HER2). Conclusions : ICI induced regression in some tumors with actionable driver alterations, but clinical activity was lower compared with the KRAS group and the lack of response in the ALK group was notable. Patients with actionable tumor alterations should receive targeted therapies and chemotherapy before considering immunotherapy as a single agent.
Collapse
Affiliation(s)
- J Mazieres
- Thoracic Oncology Department, Toulouse University Hospital, Université Paul Sabatier, Toulouse, France.
| | - A Drilon
- Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, USA
| | - A Lusque
- Biostatistics Unit, Institut Claudius Regaud, IUCT-O, Toulouse
| | - L Mhanna
- Thoracic Oncology Department, Toulouse University Hospital, Université Paul Sabatier, Toulouse, France
| | - A B Cortot
- Thoracic Oncology Department, Lille University Hospital, Lille University, Lille
| | - L Mezquita
- Cancer Medicine Department, Gustave Roussy, Villejuif, Paris Sud University Orsay, Paris France
| | - A A Thai
- Medical Oncology Department, Peter MacCallum Cancer Institute, Melbourne, Australia
| | - C Mascaux
- Multidisciplinary Oncology and Therapeutic Innovations Department, Assistance Publique Hôpitaux de Marseille, Aix Marseille University, CNRS, INSERM, CRCM, Marseille
| | - S Couraud
- Respiratory Diseases and Thoracic Oncology Department, Lyon Sud Hospital, Cancer Institute of Hospices Civils de Lyon, Lyon 1 University
| | - R Veillon
- CHU Bordeaux, Respiratory Diseases Department, Bordeaux, France
| | - M Van den Heuvel
- Faculty of Medical Science, Radboud University Medical Center, Nijmegen, The Netherlands
| | - J Neal
- Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University, Stanford, USA
| | - N Peled
- Soroka Medical Center, Ben-Gurion University, Beer-Sheva, Israel
| | - M Früh
- Department of Oncology, Haematology, Cantonal Hospital St Gallen, St Gallen, University of Bern, Switzerland
| | - T L Ng
- Thoracic Oncology Department, University of Colorado Cancer Center, Aurora, USA
| | - V Gounant
- Department of Thoracic Oncology, CIC1425-CLIP2 Paris-Nord, Bichat-Claude Bernard Hospital, APHP, Paris, France
| | - S Popat
- Royal Marsden Hospital, London, UK
| | - J Diebold
- Cantonal Hospital, Lucerne, Switzerland
| | - J Sabari
- Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, USA
| | - V W Zhu
- Department of Medicine, Division of Hematology-Oncology, University of California, Irvine School of Medicine, Orange, USA
| | - S I Rothschild
- Department Internal Medicine, University Hospital Basel, Medical Oncology, Basel, Switzerland
| | - P Bironzo
- Department of Oncology, University of Torino, Torino, Italy
| | - A Martinez-Marti
- Medical Oncology Department, Vall d'Hebron Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain
| | | | - R Rosell
- Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona; Germans Trias i Pujol Research Institute (IGTP), Badalona, Spain
| | - M Lattuca-Truc
- Pulmonology Department, Grenoble University Hospital, Grenoble, France
| | - M Wiesweg
- Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University Duisburg-Essen, Essen, Germany
| | - B Besse
- Cancer Medicine Department, Gustave Roussy, Villejuif, Paris Sud University Orsay, Paris France
| | - B Solomon
- Medical Oncology Department, Peter MacCallum Cancer Institute, Melbourne, Australia
| | - F Barlesi
- Multidisciplinary Oncology and Therapeutic Innovations Department, Assistance Publique Hôpitaux de Marseille, Aix Marseille University, CNRS, INSERM, CRCM, Marseille
| | - R D Schouten
- Faculty of Medical Science, Radboud University Medical Center, Nijmegen, The Netherlands
| | - H Wakelee
- Division of Oncology, Department of Medicine, Stanford Cancer Institute, Stanford University, Stanford, USA
| | - D R Camidge
- Thoracic Oncology Department, University of Colorado Cancer Center, Aurora, USA
| | - G Zalcman
- Department of Thoracic Oncology, CIC1425-CLIP2 Paris-Nord, Bichat-Claude Bernard Hospital, APHP, Paris, France
| | - S Novello
- Department of Oncology, University of Torino, Torino, Italy
| | - S I Ou
- Department of Medicine, Division of Hematology-Oncology, University of California, Irvine School of Medicine, Orange, USA
| | - J Milia
- Thoracic Oncology Department, Toulouse University Hospital, Université Paul Sabatier, Toulouse, France
| | - O Gautschi
- University of Bern and Cantonal Hospital, Lucerne, Switzerland
| |
Collapse
|
13
|
Feller A, Bopp M, Lorez M, Zellweger U, Adam M, Curjuric I, Staehelin K, Perren A, Bergeron Y, Rapiti E, Mousavi M, Diebold J, Dyntar D, Bulliard JL, Maspoli Conconi M, Bordoni A, Konzelmann I, Wagner U, Rohrmann S. Comment on: Wiser et al. Ovarian cancer in Switzerland: incidence and treatment according to hospital registry data. Swiss Med Wkly.2018;148:w14647. Swiss Med Wkly 2020; 150:w20179. [DOI: 10.4414/smw.2020.20179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Affiliation(s)
- Anita Feller
- Foundation National Institute for Cancer Epidemiology and Registration (NICER), Zurich, Switzerland
| | - Matthias Bopp
- Division of Chronic Disease Epidemiology, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Switzerland
| | - Matthias Lorez
- Foundation National Institute for Cancer Epidemiology and Registration (NICER), Zurich, Switzerland
| | - Ulrich Zellweger
- Division of Chronic Disease Epidemiology, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Switzerland
| | - Martin Adam
- Foundation Cancer Registry Aargau, Switzerland
| | | | | | - Aurel Perren
- Cancer Registry Bern Solothurn, Bern, Switzerland
| | | | | | - Mohsen Mousavi
- Cancer Registry East Switzerland, St Gallen, Switzerland / Cancer Registry Grison and Glarus, Chur, Switzerland
| | | | | | - Jean-Luc Bulliard
- Vaud Cancer Registry, Centre for Primary Care and Public Health (Unisanté), University of Lausanne, Switzerland / Neuchâtel and Jura Cancer Registry, Neuchâtel, Switzerland
| | | | | | | | - Ulrich Wagner
- Foundation National Institute for Cancer Epidemiology and Registration (NICER), Zurich, Switzerland
| | - Sabine Rohrmann
- Division of Chronic Disease Epidemiology, Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Switzerland / Cancer Registry of the canton Zurich and Zug, Zurich, Switzerland
| |
Collapse
|
14
|
Gautschi O, Menon R, Bertrand M, Murer C, Diebold J. Capmatinib and Osimertinib Combination Therapy for EGFR-Mutant Lung Adenocarcinoma. J Thorac Oncol 2020; 15:e13-e15. [DOI: 10.1016/j.jtho.2019.07.027] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2019] [Accepted: 07/26/2019] [Indexed: 10/25/2022]
|
15
|
Hofer S, Diebold J, Temming P, Lohmann D, Howell J, Moulin A, Beck-Popovic M, Sahm F, Milde T, Ecker J. Retinoblastoma with late metastatic spread-a case report. Pediatr Blood Cancer 2019; 66:e27656. [PMID: 30724037 DOI: 10.1002/pbc.27656] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/20/2018] [Revised: 01/18/2019] [Accepted: 01/27/2019] [Indexed: 11/08/2022]
Affiliation(s)
- Silvia Hofer
- Division of Medical Oncology, Cantonal Hospital Lucerne, Lucerne, Switzerland
| | - Joachim Diebold
- Department of Pathology, Cantonal Hospital Lucerne, Lucerne, Switzerland
| | - Petra Temming
- Pediatrics III, Department of Pediatric Oncology and Hematology, University Hospital Essen, Essen, Germany
| | - Dietmar Lohmann
- Eye Cancer Genetics, Institute of Human Genetics, University Hospital Essen, Essen, Germany
| | - Jeremy Howell
- Department of Ophthalmology, Cantonal Hospital Lucerne, Lucerne, Switzerland
| | - Alexandre Moulin
- Jules-Gonin Eye Hospital, University of Lausanne, Lausanne, Switzerland
| | - Maja Beck-Popovic
- Pediatric Hematology Oncology Unit, University Hospital CHUV, Lausanne, Switzerland
| | - Felix Sahm
- Department of Neuropathology, University Hospital Heidelberg, Heidelberg, Germany.,Clinical Cooperation Unit Neuropathology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.,Hopp Children's Cancer Center (KiTZ), Heidelberg University Hospital, Heidelberg, Germany
| | - Till Milde
- Hopp Children's Cancer Center (KiTZ), Heidelberg University Hospital, Heidelberg, Germany.,Clinical Cooperation Unit Pediatric Oncology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.,KiTZ Clinical Trial Unit (ZIPO), Department of Pediatric Hematology and Oncology, Heidelberg University Hospital, Heidelberg, Germany
| | - Jonas Ecker
- Hopp Children's Cancer Center (KiTZ), Heidelberg University Hospital, Heidelberg, Germany.,Clinical Cooperation Unit Pediatric Oncology, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.,KiTZ Clinical Trial Unit (ZIPO), Department of Pediatric Hematology and Oncology, Heidelberg University Hospital, Heidelberg, Germany
| |
Collapse
|
16
|
Michels S, Heydt C, van Veggel B, Deschler-Baier B, Pardo N, Monkhorst K, Rüsseler V, Stratmann J, Griesinger F, Steinhauser S, Kostenko A, Diebold J, Fassunke J, Fischer R, Engel-Riedel W, Gautschi O, Geissinger E, Haneder S, Ihle MA, Kopp HG, de Langen AJ, Martinez-Marti A, Nogova L, Persigehl T, Plenker D, Puesken M, Rodermann E, Rosenwald A, Scheel AH, Scheffler M, Spengler W, Seggewiss-Bernhardt R, Brägelmann J, Sebastian M, Vrugt B, Hellmich M, Sos ML, Heukamp LC, Felip E, Merkelbach-Bruse S, Smit EF, Büttner R, Wolf J. Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung Cancer. JCO Precis Oncol 2019; 3:1800210. [PMID: 32914023 PMCID: PMC7446436 DOI: 10.1200/po.18.00210] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/30/2018] [Indexed: 12/23/2022] Open
Abstract
PURPOSE Third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective in acquired resistance (AR) to early-generation EGFR TKIs in EGFR-mutant lung cancer. However, efficacy is marked by interindividual heterogeneity. We present the molecular profiles of pretreatment and post-treatment samples from patients treated with third-generation EGFR TKIs and their impact on treatment outcomes. METHODS Using the databases of two lung cancer networks and two lung cancer centers, we molecularly characterized 124 patients with EGFR p.T790M-positive AR to early-generation EGFR TKIs. In 56 patients, correlative analyses of third-generation EGFR TKI treatment outcomes and molecular characteristics were feasible. In addition, matched post-treatment biopsy samples were collected for 29 patients with progression to third-generation EGFR TKIs. RESULTS Co-occurring genetic aberrations were found in 74.4% of EGFR p.T790-positive samples (n = 124). Mutations in TP53 were the most frequent aberrations detected (44.5%; n = 53) and had no significant impact on third-generation EGFR TKI treatment. Mesenchymal-epithelial transition factor (MET) amplifications were found in 5% of samples (n = 6) and reduced efficacy of third-generation EGFR TKIs significantly (eg, median progression-free survival, 1.0 months; 95% CI, 0.37 to 1.72 v 8.2 months; 95% CI, 1.69 to 14.77 months; P ≤ .001). Genetic changes in the 29 samples with AR to third-generation EGFR TKIs were found in EGFR (eg, p.T790M loss, acquisition of p.C797S or p.G724S) or in other genes (eg, MET amplification, KRAS mutations). CONCLUSION Additional genetic aberrations are frequent in EGFR-mutant lung cancer and may mediate innate and AR to third-generation EGFR TKIs. MET amplification was strongly associated with primary treatment failure and was a common mechanism of AR to third-generation EGFR TKIs. Thus, combining EGFR inhibitors with TKIs targeting common mechanisms of resistance may delay AR.
Collapse
Affiliation(s)
| | - Carina Heydt
- University Hospital of Cologne, Cologne, Germany
| | | | - Barbara Deschler-Baier
- University Hospital of Würzburg and Comprehensive Cancer Center Mainfranken, Würzburg, Germany
| | - Nuria Pardo
- Vall d'Hebron University Hospital, Barcelona, Spain
| | - Kim Monkhorst
- Netherlands Cancer Institute, Amsterdam, the Netherlands
| | | | - Jan Stratmann
- University Hospital of Frankfurt, Frankfurt, Germany
| | - Frank Griesinger
- Pius Hospital Oldenburg and Lung Cancer Network NOWEL, Oldenburg, Germany
| | | | | | | | | | | | | | | | - Eva Geissinger
- University of Würzburg and Comprehensive Cancer Center Mainfranken, Würzburg, Germany
| | | | | | - Hans-Georg Kopp
- Robert Bosch Centrum für Tumorerkrankungen, Stuttgart, Germany
| | | | | | - Lucia Nogova
- University Hospital of Cologne, Cologne, Germany
| | | | | | | | - Ernst Rodermann
- Private practice in Hematology and Oncology, Troisdorf, Germany
| | - Andreas Rosenwald
- University of Würzburg and Comprehensive Cancer Center Mainfranken, Würzburg, Germany
| | | | | | | | | | - Johannes Brägelmann
- University Hospital of Cologne, Cologne, Germany.,University of Cologne, Cologne, Germany
| | | | - Bart Vrugt
- University Hospital Zurich, Zurich, Switzerland
| | | | - Martin L Sos
- University Hospital of Cologne, Cologne, Germany.,University of Cologne, Cologne, Germany
| | - Lukas C Heukamp
- Hematopathology Hamburg and Lung Cancer Network NOWEL, Hamburg, Germany
| | | | | | - Egbert F Smit
- Netherlands Cancer Institute, Amsterdam, the Netherlands
| | | | - Jürgen Wolf
- University Hospital of Cologne, Cologne, Germany
| |
Collapse
|
17
|
Papassotiropoulos B, Güth U, Chiesa F, Rageth C, Amann E, Baege A, Elfgen C, Varga Z, Moskovszky L, Endhardt K, Masser R, Tinguely M, Farhadi J, Lardi A, Dammann F, Diebold J, Li Q, Dubsky P, Tausch C. Prospective Evaluation of Residual Breast Tissue After Skin- or Nipple-Sparing Mastectomy: Results of the SKINI-Trial. Ann Surg Oncol 2019; 26:1254-1262. [PMID: 30830538 DOI: 10.1245/s10434-019-07259-1] [Citation(s) in RCA: 37] [Impact Index Per Article: 7.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2019] [Indexed: 11/18/2022]
Abstract
OBJECTIVE This study was designed to investigate the presence of residual breast tissue (RBT) after skin-sparing mastectomy (SSM) and nipple-sparing mastectomy (NSM) and to analyse patient- and therapy-related factors associated with RBT. Skin-sparing mastectomy and NSM are increasingly used surgical procedures. Prospective data on the completeness of breast tissue resection is lacking. However, such data are crucial for assessing oncologic safety of risk-reducing and curative mastectomies. METHODS Between April 2016 and August 2017, 99 SSM and 61 NSM were performed according to the SKINI-trial protocol, under either curative (n = 109) or risk-reducing (n = 51) indication. After breast removal, biopsies from the skin envelope (10 biopsies per SSM, 14 biopsies per NSM) were taken in predefined radial localizations and assessed histologically for the presence of RBT and of residual disease. RESULTS Residual breast tissue was detected in 82 (51.3%) mastectomies. The median RBT percentage per breast was 7.1%. Of all factors considered, only type of surgery (40.4% for SSM vs. 68.9% for NSM; P < 0.001) and surgeon (P < 0.001) were significantly associated with RBT. None of the remaining factors, e.g., skin flap necrosis, was associated significantly with RBT. Residual disease was detected in three biopsies. CONCLUSIONS Residual breast tissue is commonly observed after SSM and NSM. In contrast, invasive or in situ carcinomas are rarely found in the skin envelope. Radicality of mastectomy in this trial is not associated with increased incidence of skin flap necrosis. ClinicalTrials.gov Identifier NCT03470909.
Collapse
Affiliation(s)
| | - Uwe Güth
- Department of Breast Surgery, Brust-Zentrum, Zurich, Switzerland
| | - Federica Chiesa
- Department of Breast Surgery, Brust-Zentrum, Zurich, Switzerland
| | - Christoph Rageth
- Department of Breast Surgery, Brust-Zentrum, Zurich, Switzerland
| | - Esther Amann
- Department of Breast Surgery, Brust-Zentrum, Zurich, Switzerland
| | - Astrid Baege
- Department of Breast Surgery, Brust-Zentrum, Zurich, Switzerland
| | - Constanze Elfgen
- Department of Breast Surgery, Brust-Zentrum, Zurich, Switzerland
| | - Zsuzsanna Varga
- Institute of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland
| | - Linda Moskovszky
- Institute of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland
| | - Katharina Endhardt
- Institute of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland
| | | | | | - Jian Farhadi
- Department of Plastic Surgery, Brust-Zentrum, Zurich, Switzerland
| | - Alessia Lardi
- Department of Plastic Surgery, Brust-Zentrum, Zurich, Switzerland
| | | | | | - Qiyu Li
- Statistician Unit, Swiss Group for Clinical Cancer Research, Bern, Switzerland
| | - Peter Dubsky
- Breast Center, Hirslanden Clinic St. Anna, Lucerne, Switzerland.,Department of Surgery, Medical University of Vienna, Vienna, Austria
| | - Christoph Tausch
- Department of Breast Surgery, Brust-Zentrum, Zurich, Switzerland
| |
Collapse
|
18
|
Egli-Gany D, Spaar Zographos A, Diebold J, Masserey Spicher V, Frey Tirri B, Heusser R, Dillner J, Petignat P, Sahli R, Low N. Human papillomavirus genotype distribution and socio-behavioural characteristics in women with cervical pre-cancer and cancer at the start of a human papillomavirus vaccination programme: the CIN3+ plus study. BMC Cancer 2019; 19:111. [PMID: 30700274 PMCID: PMC6354352 DOI: 10.1186/s12885-018-5248-y] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2018] [Accepted: 12/26/2018] [Indexed: 11/11/2022] Open
Abstract
BACKGROUND The Swiss Federal Office of Public Health has recommended vaccination against human papillomavirus (HPV) to prevent cervical cancer since 2008. To establish monitoring of the future public health impact of vaccination, baseline population-based data are required. The objectives of this study were to examine the distribution of oncogenic HPV genotypes in biopsies with cervical intraepithelial neoplasia stage 3 or more severe lesions (CIN3+) at the beginning of HPV vaccination programmes and to compare sociodemographic and behavioural factors of women with CIN3+ with women in the Swiss general population. METHODS We conducted a retrospective and prospective cross-sectional study with women diagnosed with CIN3+ in Switzerland. Ten pathology institutes from six cantons and three language regions participated. We conducted HPV typing on formaldehyde fixed-paraffin embedded specimens from 2014 and 2015. Women enrolled in 2015 were asked to complete a questionnaire. We described frequencies of HPV types. We also compared demographic characteristics and socioeconomic status in the CIN3 + plus group with the Swiss National Cohort in 2014 and compared risk factors for HPV infection with the Swiss Health Survey in 2012. RESULTS We included 768 biopsies from 767 women. Four hundred and seventy-five (61.8%) biopsies were positive for HPV 16 and/or 18, 687 (89.5%) were positive for oncogenic HPV genotypes 16, 18, 31, 33, 45, 52, and/or 58 and five (0.7%) were HPV negative. Twenty-eight (10.3%) of the 273 women who completed the patient questionnaire reported having received at least one dose of an HPV vaccine. When compared with Swiss women in the six study cantons, fewer women in the CIN3+ plus study group were of Swiss nationality, more were born abroad and more were single. The study group also had a higher proportion of women with ≥2 partners in the last year, current smokers and was younger at age of first sexual intercourse. CONCLUSIONS Introduction of the nonavalent vaccine could cover approximately 90% of CIN3+ lesions in Swiss women compared with around 60% with the quadrivalent vaccine. Surveillance of HPV genotype distribution in CIN3+, together with information about vaccination and CIN3+ incidence will allow monitoring of the public health impact of vaccination programmes. TRIAL REGISTRATION ClinicalTrials.gov, NCT02323997 . Registered 24 December 2014.
Collapse
Affiliation(s)
- Dianne Egli-Gany
- Institute of Social and Preventive Medicine, University of Bern, Mittelstrasse 43, 3012 Bern, Switzerland
| | - Anne Spaar Zographos
- Federal Office of Public Health, Schwarzenburgstrasse 157, 3003 Bern, Switzerland
| | - Joachim Diebold
- Institute of Pathology, Cantonal Hospital Lucerne, Spitalstrasse, 6000 Luzern 16, Switzerland
| | | | - Brigitte Frey Tirri
- Department of Gynaecology and Obstetrics, Kantonsspital Baselland, Rheinstrasse 26, 4410 Liestal, Switzerland
| | - Rolf Heusser
- National Institute for Cancer Epidemiology and Registration, Hirschengraben 82, 8001 Zurich, Switzerland
| | - Joakim Dillner
- WHO HPV LabNet Global Reference Laboratory, Department of Clinical Microbiology, Center for Cervical Cancer Prevention, Skåne University Hospital, Malmö, Karolinska Institute and Hospital, SE-171, 77 Stockholm, Sweden
| | - Patrick Petignat
- Department of Gynaecology and Obstetrics, Geneva University Hospitals, Boulevard de la Cluse 30, 1205 Genève, Switzerland
| | - Roland Sahli
- Institute of Microbiology, Lausanne University Hospital and University of Lausanne, Rue du Bugnon 48, 1011 Lausanne, Switzerland
| | - Nicola Low
- Institute of Social and Preventive Medicine, University of Bern, Mittelstrasse 43, 3012 Bern, Switzerland
| |
Collapse
|
19
|
Uyulmaz S, Zünd M, Caspar U, Diebold J, Slankamenac K. Ileoileal intussusception in unspecific recurrent abdominal pain in adult: A case report. SAGE Open Med Case Rep 2018; 6:2050313X18792814. [PMID: 30116530 PMCID: PMC6088483 DOI: 10.1177/2050313x18792814] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2018] [Accepted: 07/09/2018] [Indexed: 12/19/2022] Open
Abstract
Primary small bowel tumours are very uncommon accounting about 1% of all gastrointestinal tumours. Intestinal lipomas are a rare entity of benign tumours with an incidence at autopsy ranging from 0.04% to 4.5%, most being asymptomatic. Complications such as obstruction, haemorrhage, intussusception and perforation might demand invasive management. Among these, intussusception is the most rare complication of intestinal lipomas. Here, we present a case of intussusception in a 52-year-old female with a large intramural lipoma of the ileum.
Collapse
Affiliation(s)
- Sema Uyulmaz
- Surgical Clinic, Zuger Kantonsspital AG, Baar, Switzerland
| | - Michael Zünd
- Surgical Clinic, Zuger Kantonsspital AG, Baar, Switzerland
| | - Uwe Caspar
- Department of Radiology, Zuger Kantonsspital AG, Baar, Switzerland
| | - Joachim Diebold
- Department of Pathology, Luzerner Kantonsspital, Lucerne, Switzerland
| | | |
Collapse
|
20
|
Zhong Q, Wagner U, Kurt H, Molinari F, Cathomas G, Komminoth P, Barman-Aksözen J, Schneider-Yin X, Rey JP, Vassella E, Rogel U, Diebold J, McKee T, Jochum W, Kashofer K, Hofman P, Zischka M, Moch H, Rechsteiner M, Wild PJ. Multi-laboratory proficiency testing of clinical cancer genomic profiling by next-generation sequencing. Pathol Res Pract 2018; 214:957-963. [PMID: 29807778 DOI: 10.1016/j.prp.2018.05.020] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/20/2017] [Revised: 05/15/2018] [Accepted: 05/19/2018] [Indexed: 01/08/2023]
Abstract
Next-generation sequencing (NGS) enables parallel analysis of multiple genomic targets. The increasing demand for NGS-based multiplexed molecular diagnostics requires standardized protocols and recommendations to ensure reproducibility and accuracy of test results for routine clinical decision making. However, the lack of clinical NGS data from multi-laboratory tests and the absence of inter-laboratory comparisons have hampered the establishment of instructive clinical NGS standards. To fill the gap, we set up Proficiency Testing (PT) for inter-laboratory comparison, in which formalin-fixed paraffin-embedded specimens from eight lung and eight colon cancers were analyzed by 15 European molecular diagnostic laboratories on three different platforms using multiple target enrichment systems. We first performed platform, test, and informatics pipeline validation and conducted sensitivity and specificity analysis by random in silico down-sampling. We then implemented a multi-level filtering strategy based on performance tests of base substitution, replicate runs, and Sanger sequencing verified variants. We finally applied the filter criteria to the NGS data from the respective PT participants and obtained high inter-laboratory agreement. We demonstrated accuracy, scalability, and robustness of NGS by means of PT, serving as a benchmark for detecting clinically actionable molecular alterations in research and diagnostic laboratories. In conclusion, this study strongly highlights the importance of establishing standards for NGS-based testing, particularly when the test results impact on clinical decisions, and systematically provides data sets from multiple different labs to infer such standards.
Collapse
Affiliation(s)
- Qing Zhong
- Department of Pathology and Molecular Pathology, University Hospital Zurich, 8091, Zurich, Switzerland; Children's Medical Research Institute, University of Sydney, 2145, Westmead, Australia
| | - Ulrich Wagner
- Department of Pathology and Molecular Pathology, University Hospital Zurich, 8091, Zurich, Switzerland
| | | | | | - Gieri Cathomas
- Institute of Pathology, Hospital Baselland, 4410, Liestal, Switzerland
| | - Paul Komminoth
- Institute of Pathology, Hospital Triemli, 8063, Zurich, Switzerland
| | | | | | | | - Erik Vassella
- Institute of Pathology, University Bern, 3010, Bern, Switzerland
| | - Uwe Rogel
- Institute of Pathology, Hospital Baden, 5404, Baden, Switzerland
| | - Joachim Diebold
- Institute of Pathology, Hospital Luzern, 6000, Luzern, Switzerland
| | - Thomas McKee
- Institute of Pathology, University Geneva, 1211, Geneva, Switzerland
| | - Wolfram Jochum
- Institute of Pathology, Hospital St. Gallen, 9007, St. Gallen, Switzerland
| | - Karl Kashofer
- Institute of Pathology, Medical University Graz, 8036, Graz, Austria
| | - Paul Hofman
- Institute of Pathology, Hospital Nice, CS, 91179, Nice, France
| | - Melanie Zischka
- Institute of Pathology, Hannover Medical School, 30625, Hannover, Germany
| | - Holger Moch
- Department of Pathology and Molecular Pathology, University Hospital Zurich, 8091, Zurich, Switzerland
| | - Markus Rechsteiner
- Department of Pathology and Molecular Pathology, University Hospital Zurich, 8091, Zurich, Switzerland.
| | - Peter J Wild
- Department of Pathology and Molecular Pathology, University Hospital Zurich, 8091, Zurich, Switzerland; Senckenberg Institute of Pathology, University Hospital Frankfurt, 60590, Frankfurt, Germany.
| |
Collapse
|
21
|
Ochs K, Meili G, Diebold J, Arndt V, Günthert A. Incidence Trends of Cervical Cancer and Its Precancerous Lesions in Women of Central Switzerland from 2000 until 2014. Front Med (Lausanne) 2018; 5:58. [PMID: 29616221 PMCID: PMC5864899 DOI: 10.3389/fmed.2018.00058] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2017] [Accepted: 02/19/2018] [Indexed: 01/15/2023] Open
Abstract
Objective Cervical cancer (CC) screening by Pap smears has led to a decrease in the incidence of CC worldwide. Indeed, the incidence of CC in Switzerland is very low; however, there is a lack of data to evaluate the efficiency of the Pap smear as a screening tool. Until now, only Pap smears have been used and other methods such as the presence of an infection with HPV have not been integrated into the routine screening. The aim of this study is to evaluate trends in the incidence of CC and its precancerous lesions in Central Switzerland, which represents a rural region, with those in urban regions and the entire country of Switzerland. Methods All conizations and CC registered between 2000 and 2014 at the Institute of Pathology at the Cantonal Hospital of Lucerne have been included in our study. The incidence of CC and its precancerous lesions have been categorized according to age, stage, morphology, and study period. Age-standardized incidence in the Canton of Zurich and the entire country served as reference for the assessment of trends in CC incidence in the study region. Results In Central Switzerland, the number of conizations performed annually has more than doubled over the observed 15 years. There has been a significant increase in precancerous lesions, which were found in approximately 50% of conizations. The total number of CC diagnosed by conization increased by 37.5% and the total of CIN3 increased by 130%. Age-standardized incidence of CC and CIN3 increased from 2.4 to 3.3/100,000 and from 11.6 to 26.9/100,000, respectively. The incidence of CC was lower in Central Switzerland compared to incidence in the Canton of Zurich and in Switzerland generally. Conclusion Approximately 50% of all conizations were performed on women without serious precancerous lesions. For this reason, we recommend the adaptation of screening modalities and the use of risk stratification to avoid overtreatment. In light of the forthcoming implementation of an HPV vaccination program, our data provides important baseline information.
Collapse
Affiliation(s)
- Katrin Ochs
- Department of Obstetrics and Gynecology, Cantonal Hospital of Lucerne, Lucerne, Switzerland
| | - Gesine Meili
- Department of Obstetrics and Gynecology, Cantonal Hospital of Lucerne, Lucerne, Switzerland
| | - Joachim Diebold
- Institute of Pathology, Cantonal Hospital of Lucerne, Lucerne, Switzerland
| | - Volker Arndt
- Foundation National Institute for Cancer Epidemiology and Registration (NICER), Zurich, Switzerland
| | - Andreas Günthert
- Department of Obstetrics and Gynecology, Cantonal Hospital of Lucerne, Lucerne, Switzerland
| |
Collapse
|
22
|
Banks P, Brown R, Laslowski A, Daniels Y, Branton P, Carpenter J, Zarbo R, Forsyth R, Liu YH, Kohl S, Diebold J, Masuda S, Plummer T, Dennis E. A Proposed Set of Metrics to Reduce Patient Safety Risk From Within the Anatomic Pathology Laboratory. Lab Med 2017; 48:195-201. [PMID: 28340232 PMCID: PMC5424539 DOI: 10.1093/labmed/lmw068] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
Abstract
Background: Anatomic pathology laboratory workflow consists of 3 major specimen handling processes. Among the workflow are preanalytic, analytic, and postanalytic phases that contain multistep subprocesses with great impact on patient care. A worldwide representation of experts came together to create a system of metrics, as a basis for laboratories worldwide, to help them evaluate and improve specimen handling to reduce patient safety risk. Method: Members of the Initiative for Anatomic Pathology Laboratory Patient Safety (IAPLPS) pooled their extensive expertise to generate a list of metrics highlighting processes with high and low risk for adverse patient outcomes. Results: Our group developed a universal, comprehensive list of 47 metrics for patient specimen handling in the anatomic pathology laboratory. Steps within the specimen workflow sequence are categorized as high or low risk. In general, steps associated with the potential for specimen misidentification correspond to the high-risk grouping and merit greater focus within quality management systems. Primarily workflow measures related to operational efficiency can be considered low risk. Conclusion: Our group intends to advance the widespread use of these metrics in anatomic pathology laboratories to reduce patient safety risk and improve patient care with development of best practices and interlaboratory error reporting programs.
Collapse
Affiliation(s)
- Peter Banks
- Medical Affairs, Ventana Medical Systems Inc., Tucson, AZ
| | - Richard Brown
- Laboratory Services, Memorial Hermann Southeast Hospital, Houston, TX
| | - Alex Laslowski
- Department of Laboratory Medicine, Monash Medical Centre, Clayton, Victoria, Australia
| | - Yvonne Daniels
- Department of Pathology, East Carolina University, Greenville, NC
| | - Phil Branton
- Biorepositories and Biospecimens Research Branch, Cancer Diagnosis Program, National Institutes of Health, Bethesda, MD
| | - John Carpenter
- Division of Pathology, Puget Sound Gastroenterology Medical Center, Lynnwood, WA
| | - Richard Zarbo
- Pathology and Laboratory Medicine, Henry Ford Health System, Detroit, MI
| | - Ramses Forsyth
- Department of Pathology, Universitair Ziekenhuis Brussels, Brussels, Belgium
| | - Yan-Hui Liu
- Department of Pathology, Guangdong General Hospital, Guangdong Academy of Medical Science Guangdong Province, China
| | - Shane Kohl
- Anatomic & Clinical Pathology, Nebraska Methodist Health System, Inc, Omaha, NE
| | - Joachim Diebold
- Leiter Departement Institute, Luzerner Kantonsspital, Lucerne, Switzerland
| | - Shinobu Masuda
- Department of Pathology, Nihon University School of Medicine, Tokyo, Japan
| | - Tim Plummer
- Operations Division, Mayo Clinic, Mayo College of Medicine, Rochester, MN
| | - Eslie Dennis
- Medical Affairs, Ventana Medical Systems Inc., Tucson, AZ
| |
Collapse
|
23
|
Schwegler C, Kaufmann D, Pfeiffer D, Aebi S, Diebold J, Gautschi O. Population-level effect of molecular testing and targeted therapy in patients with advanced pulmonary adenocarcinoma: a prospective cohort study. Virchows Arch 2017; 472:581-588. [PMID: 29198034 DOI: 10.1007/s00428-017-2268-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2017] [Revised: 11/01/2017] [Accepted: 11/09/2017] [Indexed: 11/26/2022]
Abstract
Large cancer centres in the USA demonstrated that molecular diagnosis and targeted therapy improved overall survival of patients with advanced pulmonary adenocarcinoma. We validated this finding in a rural area of Switzerland, served by private practices, community hospitals and a tertiary referral centre. We conducted a prospective cohort study with the Cancer Registry of Central Switzerland, covering 4 cantons and 517,000 inhabitants. All residents newly diagnosed with stage IV pulmonary adenocarcinoma from 2010 to 2014 were enrolled. We obtained information on patients, tumour, molecular testing, therapy and survival. Three hundred forty-eight patients were included in the study. Molecular testing was performed in 279 (80%); 132 (38%) had oncogenic driver mutations: Kirsten rat sarcoma (KRAS, 16%), epidermal growth factor receptor (EGFR, 11%), anaplastic lymphoma kinase (ALK, 5%), human epidermal growth factor receptor 2 (HER2, 2%), B rapidly accelerated fibrosarcoma (BRAF, 1%), rearranged during transfection (RET, 0.5%), MET proto-oncogene (0.5%) and multiple mutations (2%). Fifty-six patients with an oncogenic driver mutation, mostly epidermal growth factor receptor (34) and anaplastic lymphoma kinase (12), received genotype-matched targeted therapy, at least 25 (45%) of whom in a clinical trial or named patient programme. Median overall survival was 18 months for patients with driver mutations and targeted therapy, 8 months for patients with driver mutations and conventional therapy and 10 months for patients with no driver mutation and conventional therapy. For patients with driver mutations and targeted therapy, overall survival was significantly better than that for patients with driver mutations and conventional therapy (HR 0.64, p = 0.04). Rigorous testing combined with optimal access to targeted therapy in clinical trials improved the prognosis of patients with advanced pulmonary adenocarcinoma in Central Switzerland. This effect was mainly driven by therapies targeting epidermal growth factor receptor and anaplastic lymphoma kinase.
Collapse
Affiliation(s)
- Christine Schwegler
- Cancer Registry of Central Switzerland, Cantonal Hospital Lucerne, Lucerne, Switzerland.
| | - Dinu Kaufmann
- Institute of Computer Science, University of Basel, Basel, Switzerland
| | - David Pfeiffer
- Cancer Registry of Central Switzerland, Cantonal Hospital Lucerne, Lucerne, Switzerland
- Institute of Pathology, Cantonal Hospital Lucerne, Lucerne, Switzerland
| | - Stefan Aebi
- Department of Medical Oncology, Cantonal Hospital Lucerne, Lucerne, Switzerland
| | - Joachim Diebold
- Cancer Registry of Central Switzerland, Cantonal Hospital Lucerne, Lucerne, Switzerland
- Institute of Pathology, Cantonal Hospital Lucerne, Lucerne, Switzerland
| | - Oliver Gautschi
- Department of Medical Oncology, Cantonal Hospital Lucerne, Lucerne, Switzerland
| |
Collapse
|
24
|
Hübener C, Bidlingmaier M, Wu Z, Diebold J, Strasburger CJ, Mahner S, Hasbargen U, Delius M. Human placental growth hormone in ectopic pregnancy: Detection in maternal blood, immunohistochemistry and potential clinical implication. Growth Horm IGF Res 2017; 37:13-18. [PMID: 29073481 DOI: 10.1016/j.ghir.2017.10.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/22/2017] [Revised: 10/11/2017] [Accepted: 10/12/2017] [Indexed: 11/19/2022]
Abstract
OBJECTIVE To investigate human placental growth hormone (hGH-V) in ectopic pregnancy (EP): detection in maternal blood, correlation with immunohistochemistry and possible role as a marker for the course of EP. DESIGN Women presenting in the outpatient or emergency department of a tertiary care university hospital with a positive pregnancy test and strong suspicion of EP by ultrasound and/or symptoms were eligible for the study (n=70). Tissue specimens from the surgically treated patients (n=50) were examined by histopathology as well as by a hGH-V specific immohistochemistry set-up. A highly sensitive hGH-V specific immunoassay was used to analyse serum samples collected before treatment, day 1 post surgery samples and serial samples for medical treatment. RESULT(S) In EP patients' sera hGH-V was shown to be measurable for the first time (n=18). HGH-V however could not be detected in all patients' sera. HCG levels were significantly higher in the hGH-V serum positive group (p 0.001). HGH-V was localized to the syncytiotrophoblast in all specimens of EP examined by immunohistochemistry (n=10) regardless of the detection in the patient's blood. CONCLUSION(S) Placental growth hormone (hGH-V) was shown to be present both in ectopic pregnancy patients' sera and tissue. It may serve as a biomarker for monitoring the course and treatment of EP.
Collapse
Affiliation(s)
- Christoph Hübener
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, Ludwig-Maximilians-Universität München, Marchioninistr. 15, 81377 München, Germany.
| | - Martin Bidlingmaier
- Endocrine Laboratory, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Ludwig-Maximilians-Universität München, Ziemssenstraße 1, 80336 München, Germany
| | - Zida Wu
- Klinik für Endokrinologie, Diabetes und Ernährungsmedizin, Charité Universitätsmedizin Berlin, Campus Mitte, Charitéplatz 1, 10117 Berlin, Germany
| | - Joachim Diebold
- Pathologisches Institut, Kantonsspital Luzern, Luzerner Kantonsspital, 6000 Luzern 16, Switzerland
| | - Christian J Strasburger
- Klinik für Endokrinologie, Diabetes und Ernährungsmedizin, Charité Universitätsmedizin Berlin, Campus Mitte, Charitéplatz 1, 10117 Berlin, Germany
| | - Sven Mahner
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, Ludwig-Maximilians-Universität München, Marchioninistr. 15, 81377 München, Germany
| | - Uwe Hasbargen
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, Ludwig-Maximilians-Universität München, Marchioninistr. 15, 81377 München, Germany
| | - Maria Delius
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, Ludwig-Maximilians-Universität München, Marchioninistr. 15, 81377 München, Germany
| |
Collapse
|
25
|
Rey S, Quintavalle C, Burmeister K, Calabrese D, Schlageter M, Quagliata L, Cathomas G, Diebold J, Molinolo A, Heim MH, Terracciano LM, Matter MS. Liver damage and senescence increases in patients developing hepatocellular carcinoma. J Gastroenterol Hepatol 2017; 32:1480-1486. [PMID: 28052383 DOI: 10.1111/jgh.13717] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/23/2016] [Revised: 12/10/2016] [Accepted: 12/29/2016] [Indexed: 12/17/2022]
Abstract
BACKGROUND AND AIM Most patients with a hepatocellular carcinoma (HCC) have an underlying chronic liver inflammation, which causes a continuous damage leading to liver cirrhosis and eventually HCC. However, only a minority of cirrhotic patients develop HCC. To assess a possible differential impact of liver inflammation in patients developing HCC versus patients remaining tumor-free, we designed a longitudinal study and analysed liver tissue of the same patients (n = 33) at two points in time: once when no HCC was present and once several years later when an HCC was present. As a control group, we followed cirrhotic patients (n = 37) remaining tumor-free over a similar time frame. METHODS We analysed cell damage and senescence of hepatocytes by measuring γ-H2AX positivity, p16INK4 and p21WAF/Cip1 expression, nuclear size, and telomere length. RESULTS γ-H2AX positivity, p16INK4 and p21WAF/Cip1 expression, in the first liver biopsy was similar in patients developing HCC later on and cirrhotic patients remaining tumor free. In contrast, γ-H2AX positivity, p16INK4 and p21WAF/Cip1 expression, was significantly higher in the second non-tumoral liver biopsy of HCC patients than in the control patients. Consequently, the individual increase in γ-H2AX positivity, p16INK4 and p21WAF/Cip1 expression, from the first biopsy to the second biopsy was significantly higher in patients developing HCC than in patients remaining tumor free. In addition, changes in nuclear size and telomere length revealed a more pronounced cell aging in patients developing HCC than in patients remaining tumor free. CONCLUSIONS Hepatocytes from patients developing HCC go through more pronounced cell damage and senescence in contrast to cirrhotic patients remaining tumor free.
Collapse
Affiliation(s)
- Silvia Rey
- Institute of Pathology, University Hospital of Basel, Basel, Switzerland
| | | | | | - Diego Calabrese
- Department of Gastroenterology and Hepatology, University Hospital of Basel, Basel, Switzerland
| | - Manuel Schlageter
- Institute of Pathology, University Hospital of Basel, Basel, Switzerland
| | - Luca Quagliata
- Institute of Pathology, University Hospital of Basel, Basel, Switzerland
| | - Gieri Cathomas
- Institute of Pathology, Kantonsspital Baselland, Liestal, Switzerland
| | - Joachim Diebold
- Institute of Pathology, Luzerner Kantonsspital, Lucerne, Switzerland
| | | | - Markus H Heim
- Department of Gastroenterology and Hepatology, University Hospital of Basel, Basel, Switzerland
| | | | - Matthias S Matter
- Institute of Pathology, University Hospital of Basel, Basel, Switzerland
| |
Collapse
|
26
|
Plenker D, Riedel M, Brägelmann J, Dammert MA, Chauhan R, Knowles PP, Lorenz C, Keul M, Bührmann M, Pagel O, Tischler V, Scheel AH, Schütte D, Song Y, Stark J, Mrugalla F, Alber Y, Richters A, Engel J, Leenders F, Heuckmann JM, Wolf J, Diebold J, Pall G, Peifer M, Aerts M, Gevaert K, Zahedi RP, Buettner R, Shokat KM, McDonald NQ, Kast SM, Gautschi O, Thomas RK, Sos ML. Drugging the catalytically inactive state of RET kinase in RET-rearranged tumors. Sci Transl Med 2017; 9:eaah6144. [PMID: 28615362 PMCID: PMC5805089 DOI: 10.1126/scitranslmed.aah6144] [Citation(s) in RCA: 53] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2016] [Revised: 02/03/2017] [Accepted: 03/21/2017] [Indexed: 01/25/2023]
Abstract
Oncogenic fusion events have been identified in a broad range of tumors. Among them, RET rearrangements represent distinct and potentially druggable targets that are recurrently found in lung adenocarcinomas. We provide further evidence that current anti-RET drugs may not be potent enough to induce durable responses in such tumors. We report that potent inhibitors, such as AD80 or ponatinib, that stably bind in the DFG-out conformation of RET may overcome these limitations and selectively kill RET-rearranged tumors. Using chemical genomics in conjunction with phosphoproteomic analyses in RET-rearranged cells, we identify the CCDC6-RETI788N mutation and drug-induced mitogen-activated protein kinase pathway reactivation as possible mechanisms by which tumors may escape the activity of RET inhibitors. Our data provide mechanistic insight into the druggability of RET kinase fusions that may be of help for the development of effective therapies targeting such tumors.
Collapse
Affiliation(s)
- Dennis Plenker
- Molecular Pathology, Institute of Pathology, Center of Integrated Oncology, University Hospital Cologne, 50937 Cologne, Germany
- Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, 50931 Cologne, Germany
| | - Maximilian Riedel
- Molecular Pathology, Institute of Pathology, Center of Integrated Oncology, University Hospital Cologne, 50937 Cologne, Germany
- Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, 50931 Cologne, Germany
| | - Johannes Brägelmann
- Molecular Pathology, Institute of Pathology, Center of Integrated Oncology, University Hospital Cologne, 50937 Cologne, Germany
- Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, 50931 Cologne, Germany
| | - Marcel A Dammert
- Molecular Pathology, Institute of Pathology, Center of Integrated Oncology, University Hospital Cologne, 50937 Cologne, Germany
- Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, 50931 Cologne, Germany
| | - Rakhee Chauhan
- Structural Biology Laboratory, Francis Crick Institute, 44 Lincoln's Inn Fields, London WC2A 3LY, UK
| | - Phillip P Knowles
- Structural Biology Laboratory, Francis Crick Institute, 44 Lincoln's Inn Fields, London WC2A 3LY, UK
| | - Carina Lorenz
- Molecular Pathology, Institute of Pathology, Center of Integrated Oncology, University Hospital Cologne, 50937 Cologne, Germany
- Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, 50931 Cologne, Germany
| | - Marina Keul
- Faculty of Chemistry and Chemical Biology, TU Dortmund University, 44227 Dortmund, Germany
| | - Mike Bührmann
- Faculty of Chemistry and Chemical Biology, TU Dortmund University, 44227 Dortmund, Germany
| | - Oliver Pagel
- Leibniz-Institut für Analytische Wissenschaften-ISAS-e.V., Dortmund, Germany
| | - Verena Tischler
- Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, 50931 Cologne, Germany
| | - Andreas H Scheel
- Institute of Pathology, Center of Integrated Oncology, University Hospital Cologne, 50937 Cologne, Germany
| | - Daniel Schütte
- Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, 50931 Cologne, Germany
| | - Yanrui Song
- Crown BioScience, Inc., 3375 Scott Blvd, Suite 108, Santa Clara, CA 95054, USA
| | - Justina Stark
- Faculty of Chemistry and Chemical Biology, TU Dortmund University, 44227 Dortmund, Germany
| | - Florian Mrugalla
- Faculty of Chemistry and Chemical Biology, TU Dortmund University, 44227 Dortmund, Germany
| | - Yannic Alber
- Faculty of Chemistry and Chemical Biology, TU Dortmund University, 44227 Dortmund, Germany
| | - André Richters
- Faculty of Chemistry and Chemical Biology, TU Dortmund University, 44227 Dortmund, Germany
| | - Julian Engel
- Faculty of Chemistry and Chemical Biology, TU Dortmund University, 44227 Dortmund, Germany
| | | | | | - Jürgen Wolf
- Department of Internal Medicine, Center for Integrated Oncology Köln Bonn, University Hospital Cologne, Cologne, 50931 Cologne, Germany
| | - Joachim Diebold
- Cancer Center, Lucerne Cantonal Hospital, 6000 Lucerne, Switzerland
| | - Georg Pall
- Department of Internal Medicine 5, University Hospital Innsbruck, Haematology/Oncology, Anichstraße 35, 6020 Innsbruck, Austria
| | - Martin Peifer
- Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, 50931 Cologne, Germany
| | - Maarten Aerts
- VIB-UGent Center for Medical Biotechnology, VIB, B-9000 Ghent, Belgium
- Department of Biochemistry, Ghent University, B-9000 Ghent, Belgium
| | - Kris Gevaert
- VIB-UGent Center for Medical Biotechnology, VIB, B-9000 Ghent, Belgium
- Department of Biochemistry, Ghent University, B-9000 Ghent, Belgium
| | - René P Zahedi
- Leibniz-Institut für Analytische Wissenschaften-ISAS-e.V., Dortmund, Germany
| | - Reinhard Buettner
- Institute of Pathology, Center of Integrated Oncology, University Hospital Cologne, 50937 Cologne, Germany
| | - Kevan M Shokat
- Department of Cellular and Molecular Pharmacology, Howard Hughes Medical Institute, University of California, San Francisco, San Francisco, CA 94158, USA
| | - Neil Q McDonald
- Structural Biology Laboratory, Francis Crick Institute, 44 Lincoln's Inn Fields, London WC2A 3LY, UK
- Institute of Structural and Molecular Biology, Department of Biological Sciences, Birkbeck College, Malet Street, London WC1E 7HX, UK
| | - Stefan M Kast
- Faculty of Chemistry and Chemical Biology, TU Dortmund University, 44227 Dortmund, Germany
| | - Oliver Gautschi
- Cancer Center, Lucerne Cantonal Hospital, 6000 Lucerne, Switzerland
| | - Roman K Thomas
- Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, 50931 Cologne, Germany
- Department of Internal Medicine, Center for Integrated Oncology Köln Bonn, University Hospital Cologne, Cologne, 50931 Cologne, Germany
- German Cancer Consortium (DKTK), partner site Heidelberg, and German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - Martin L Sos
- Molecular Pathology, Institute of Pathology, Center of Integrated Oncology, University Hospital Cologne, 50937 Cologne, Germany.
- Department of Translational Genomics, Center of Integrated Oncology Cologne-Bonn, Medical Faculty, University of Cologne, 50931 Cologne, Germany
| |
Collapse
|
27
|
Schwegler C, Kaufmann D, Gautschi O, Aebi S, Diebold J, Pfeiffer D. Population-level effect of targeted therapy in patients with advanced pulmonary adenocarcinoma: A Swiss prospective cohort study. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx090.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
28
|
Gautschi O, Milia J, Filleron T, Wolf J, Carbone DP, Owen D, Camidge R, Narayanan V, Doebele RC, Besse B, Remon-Masip J, Janne PA, Awad MM, Peled N, Byoung CC, Karp DD, Van Den Heuvel M, Wakelee HA, Neal JW, Mok TSK, Yang JCH, Ou SHI, Pall G, Froesch P, Zalcman G, Gandara DR, Riess JW, Velcheti V, Zeidler K, Diebold J, Früh M, Michels S, Monnet I, Popat S, Rosell R, Karachaliou N, Rothschild SI, Shih JY, Warth A, Muley T, Cabillic F, Mazières J, Drilon A. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. J Clin Oncol 2017; 35:1403-1410. [PMID: 28447912 DOI: 10.1200/jco.2016.70.9352] [Citation(s) in RCA: 244] [Impact Index Per Article: 34.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Purpose In addition to prospective trials for non-small-cell lung cancers (NSCLCs) that are driven by less common genomic alterations, registries provide complementary information on patient response to targeted therapies. Here, we present the results of an international registry of patients with RET-rearranged NSCLCs, providing the largest data set, to our knowledge, on outcomes of RET-directed therapy thus far. Methods A global, multicenter network of thoracic oncologists identified patients with pathologically confirmed NSCLC that harbored a RET rearrangement. Molecular profiling was performed locally by reverse transcriptase polymerase chain reaction, fluorescence in situ hybridization, or next-generation sequencing. Anonymized data-clinical, pathologic, and molecular features-were collected centrally and analyzed by an independent statistician. Best response to RET tyrosine kinase inhibition administered outside of a clinical trial was determined by RECIST v1.1. Results By April 2016, 165 patients with RET-rearranged NSCLC from 29 centers across Europe, Asia, and the United States were accrued. Median age was 61 years (range, 29 to 89 years). The majority of patients were never smokers (63%) with lung adenocarcinomas (98%) and advanced disease (91%). The most frequent rearrangement was KIF5B-RET (72%). Of those patients, 53 received one or more RET tyrosine kinase inhibitors in sequence: cabozantinib (21 patients), vandetanib (11 patients), sunitinib (10 patients), sorafenib (two patients), alectinib (two patients), lenvatinib (two patients), nintedanib (two patients), ponatinib (two patients), and regorafenib (one patient). The rate of any complete or partial response to cabozantinib, vandetanib, and sunitinib was 37%, 18%, and 22%, respectively. Further responses were observed with lenvantinib and nintedanib. Median progression-free survival was 2.3 months (95% CI, 1.6 to 5.0 months), and median overall survival was 6.8 months (95% CI, 3.9 to 14.3 months). Conclusion Available multikinase inhibitors had limited activity in patients with RET-rearranged NSCLC in this retrospective study. Further investigation of the biology of RET-rearranged lung cancers and identification of new targeted therapeutics will be required to improve outcomes for these patients.
Collapse
Affiliation(s)
- Oliver Gautschi
- Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain
| | - Julie Milia
- Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain
| | - Thomas Filleron
- Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain
| | - Juergen Wolf
- Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain
| | - David P Carbone
- Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain
| | - Dwight Owen
- Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain
| | - Ross Camidge
- Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain
| | - Vignhesh Narayanan
- Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain
| | - Robert C Doebele
- Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain
| | - Benjamin Besse
- Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain
| | - Jordi Remon-Masip
- Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain
| | - Pasi A Janne
- Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain
| | - Mark M Awad
- Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain
| | - Nir Peled
- Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain
| | - Chul-Cho Byoung
- Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain
| | - Daniel D Karp
- Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain
| | - Michael Van Den Heuvel
- Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain
| | - Heather A Wakelee
- Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain
| | - Joel W Neal
- Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain
| | - Tony S K Mok
- Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain
| | - James C H Yang
- Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain
| | - Sai-Hong Ignatius Ou
- Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain
| | - Georg Pall
- Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain
| | - Patrizia Froesch
- Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain
| | - Gérard Zalcman
- Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain
| | - David R Gandara
- Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain
| | - Jonathan W Riess
- Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain
| | - Vamsidhar Velcheti
- Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain
| | - Kristin Zeidler
- Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain
| | - Joachim Diebold
- Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain
| | - Martin Früh
- Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain
| | - Sebastian Michels
- Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain
| | - Isabelle Monnet
- Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain
| | - Sanjay Popat
- Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain
| | - Rafael Rosell
- Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain
| | - Niki Karachaliou
- Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain
| | - Sacha I Rothschild
- Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain
| | - Jin-Yuan Shih
- Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain
| | - Arne Warth
- Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain
| | - Thomas Muley
- Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain
| | - Florian Cabillic
- Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain
| | - Julien Mazières
- Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain
| | - Alexander Drilon
- Oliver Gautschi, Kristin Zeidler, and Joachim Diebold, Lucerne Cantonal Hospital, Luzern; Patrizia Froesch, Ente Ospedaliero Cantonale, Bellinzona; Martin Früh, Kantonsspital St Gallen, St Gallen; Sacha I. Rothschild, University Hospital Basel, Basel, Switzerland; Julie Milia and Julien Mazières, Hôpital Larrey; Thomas Filleron, Institut Universitaire du Cancer, Claudius Regaud, Toulouse; Benjamin Besse and Jordi Remon-Masip, Institute Gustave Roussy, Villejuif; Gérard Zalcman, University Hospital Bichat, Paris; Isabelle Monnet, Centre Hospitalier Intercommunal de Creteil, Creteil; Florian Cabillic, Université de Rennes 1, Rennes, France; Juergen Wolf and Sebastian Michels, Center for Integrated Oncology, Cologne; Georg Pall, Fachkliniken Wangen, Wangen Im Allgäu; Arne Warth, Heidelberg University Hospital; Thomas Muley, Thoraxklinik at University of Heidelberg and Translational Lung Research Center, Heidelberg, Germany; David P. Carbone and Dwight Owen, Ohio State University Comprehensive Cancer Center, Columbus; Vamsidhar Velcheti, Cleveland Clinic, Pepper Pike, OH; Ross Camidge and Vignhesh Narayanan, University of Colorado, Denver; Robert C. Doebele, University of Colorado, Aurora, CO; Pasi A. Janne and Mark M. Awad, Dana-Farber Cancer Institute, Boston, MA; Daniel D. Karp, The University of Texas MD Anderson Cancer Center, Houston, TX; Heather A. Wakelee and Joel W. Neal, Stanford University, Stanford; Sai-Hong Ignatius Ou, University of California, Irvine, Orange; David R. Gandara and Jonathan W. Riess, University of California, Davis Cancer Center, Sacramento, CA; Alexander Drilon, Memorial Sloan Kettering Cancer Center, New York, NY; Nir Peled, Davidoff Cancer Center, Petach Tiqwa, Israël; Chul-Cho Byoung, Yonseï Cancer Center, Seoul, Republic of Korea; Michael Van Den Heuvel, Netherlands Cancer Institute, Amsterdam, the Netherlands; Tony S.K. Mok, The Chinese University of Hong Kong, Hong Kong, Special Administrative Region, People's Republic of China; James C.H. Yang and Jin-Yuan Shih, National Taiwan University Hospital, Taipei, Republic of China; Sanjay Popat, Royal Marsden Hospital, London, United Kingdom; and Rafael Rosell and Niki Karachaliou, Catalan Institute of Oncology, Barcelona, Spain
| |
Collapse
|
29
|
Michels S, Scheel AH, Scheffler M, Schultheis AM, Gautschi O, Aebersold F, Diebold J, Pall G, Rothschild S, Bubendorf L, Hartmann W, Heukamp L, Schildhaus HU, Fassunke J, Ihle MA, Künstlinger H, Heydt C, Fischer R, Nogovà L, Mattonet C, Hein R, Adams A, Gerigk U, Schulte W, Lüders H, Grohé C, Graeven U, Müller-Naendrup C, Draube A, Kambartel KO, Krüger S, Schulze-Olden S, Serke M, Engel-Riedel W, Kaminsky B, Randerath W, Merkelbach-Bruse S, Büttner R, Wolf J. Clinicopathological Characteristics of RET Rearranged Lung Cancer in European Patients. J Thorac Oncol 2016; 11:122-7. [PMID: 26762747 DOI: 10.1016/j.jtho.2015.09.016] [Citation(s) in RCA: 53] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2015] [Revised: 09/11/2015] [Accepted: 09/14/2015] [Indexed: 11/19/2022]
Abstract
INTRODUCTION Rearrangements of RET are rare oncogenic events in patients with non-small cell lung cancer (NSCLC). While the characterization of Asian patients suggests a predominance of nonsmokers of young age in this genetically defined lung cancer subgroup, little is known about the characteristics of non-Asian patients. We present the results of an analysis of a European cohort of patients with RET rearranged NSCLC. METHODS Nine hundred ninety-seven patients with KRAS/EGFR/ALK wildtype lung adenocarcinomas were analyzed using fluorescence in situ hybridization for RET fusions. Tumor specimens were molecularly profiled and clinicopathological characteristics of the patients were collected. RESULTS Rearrangements of RET were identified in 22 patients, with a prevalence of 2.2% in the KRAS/EGFR/ALK wildtype subgroup. Co-occurring genetic aberrations were detected in 10 patients, and the majority had mutations in TP53. The median age at diagnosis was 62 years (range, 39-80 years; mean ± SD, 61 ± 11.7 years) with a higher proportion of men (59% versus 41%). There was only a slight predominance of nonsmokers (54.5%) compared to current or former smokers (45.5%). CONCLUSIONS Patients with RET rearranged adenocarcinomas represent a rare and heterogeneous NSCLC subgroup. In some contrast to published data, we see a high prevalence of current and former smokers in our white RET cohort. The significance of co-occurring aberrations, so far, is unclear.
Collapse
Affiliation(s)
- Sebastian Michels
- Center for Integrated Oncology Köln Bonn, Cologne, Germany; Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany; Network Genomic Medicine, Cologne, Germany
| | - Andreas Hans Scheel
- Network Genomic Medicine, Cologne, Germany; Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Matthias Scheffler
- Center for Integrated Oncology Köln Bonn, Cologne, Germany; Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany; Network Genomic Medicine, Cologne, Germany
| | - Anne Maria Schultheis
- Network Genomic Medicine, Cologne, Germany; Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Oliver Gautschi
- Department for Medical Oncology, Lucerne Cantonal Hospital, Lucerne, Switzerland
| | | | - Joachim Diebold
- Institute of Pathology, Lucerne Cantonal Hospital, Lucerne, Switzerland
| | - Georg Pall
- Department for Internal Medicine, Haematology and Oncology, University Hospital Innsbruck, Innsbruck, Austria
| | - Sacha Rothschild
- Department for Oncology, University Hospital Basel, Basel, Switzerland
| | - Lukas Bubendorf
- Department for Cytopathology, University Hospital Basel, Basel, Switzerland
| | - Wolfgang Hartmann
- Gerhard-Domagk-Institute of Pathology, University Hospital of Münster, Münster, Germany
| | - Lukas Heukamp
- Network Genomic Medicine, Cologne, Germany; Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | | | - Jana Fassunke
- Network Genomic Medicine, Cologne, Germany; Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Michaela Angelika Ihle
- Network Genomic Medicine, Cologne, Germany; Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Helen Künstlinger
- Network Genomic Medicine, Cologne, Germany; Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Carina Heydt
- Network Genomic Medicine, Cologne, Germany; Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Rieke Fischer
- Center for Integrated Oncology Köln Bonn, Cologne, Germany; Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany; Network Genomic Medicine, Cologne, Germany
| | - Lucia Nogovà
- Center for Integrated Oncology Köln Bonn, Cologne, Germany; Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany; Network Genomic Medicine, Cologne, Germany
| | - Christian Mattonet
- Center for Integrated Oncology Köln Bonn, Cologne, Germany; Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany; Network Genomic Medicine, Cologne, Germany
| | - Rebecca Hein
- Institute of Medical Statistics, Informatics and Epidemiology, University Hospital of Cologne, Cologne, Germany
| | - Anne Adams
- Institute of Medical Statistics, Informatics and Epidemiology, University Hospital of Cologne, Cologne, Germany
| | - Ulrich Gerigk
- Thoracic Centre, Malteser Hospital Bonn/Rhein-Sieg, Bonn, Germany
| | - Wolfgang Schulte
- Departent for Pulmonology Cardiology and Allergology, Johanniter Hospital, Bonn, Germany
| | - Heike Lüders
- Evangelic Lung Clinic Berlin, Department of Pneumology, Berlin, Germany
| | - Christian Grohé
- Evangelic Lung Clinic Berlin, Department of Pneumology, Berlin, Germany
| | - Ullrich Graeven
- Department for Hematology, Oncology and Gastroenterology, Maria Hilf Hospital Mönchengladbach, Mönchengladbach, Germany
| | | | - Andreas Draube
- Department for Internal Medicine, St. Vinzenz Hospital Cologne, Cologne, Germany
| | - Karl-Otto Kambartel
- Department for Pulmonology and Allergology, Bethanien Hospital Moers, Moers, Germany
| | - Stefan Krüger
- Department for Pulmonology/Allergology/Sleep Medicine and Respiratory Care, Florence-Nightingale-Hospital, Düsseldorf, Germany
| | - Susanne Schulze-Olden
- Department for Pulmonology/Allergology/Sleep Medicine and Respiratory Care, Florence-Nightingale-Hospital, Düsseldorf, Germany
| | - Monika Serke
- Department for Pulmonology and Thoracic Oncology, Lung Clinic Hemer, Hemer, Germany
| | | | - Britta Kaminsky
- Clinic for Pulmonology and Allergology, Bethanien Hospital, Solingen, Germany
| | - Winfried Randerath
- Clinic for Pulmonology and Allergology, Bethanien Hospital, Solingen, Germany
| | - Sabine Merkelbach-Bruse
- Network Genomic Medicine, Cologne, Germany; Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Reinhard Büttner
- Network Genomic Medicine, Cologne, Germany; Institute of Pathology, University Hospital of Cologne, Cologne, Germany
| | - Jürgen Wolf
- Center for Integrated Oncology Köln Bonn, Cologne, Germany; Lung Cancer Group Cologne, Department I for Internal Medicine, University Hospital of Cologne, Cologne, Germany; Network Genomic Medicine, Cologne, Germany.
| |
Collapse
|
30
|
Staebler A, Pfisterer J, Diebold J, Lax SF, Schmidt D, Kommoss F, du Bois A, Kommoss S. Internet based second opinion pathology in a large chemotherapy trial for ovarian cancer – results of a standardized review process. Geburtshilfe Frauenheilkd 2016. [DOI: 10.1055/s-0036-1592680] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
31
|
Zander T, Aebi S, Rast AC, Zander A, Winterhalder R, Brand C, Diebold J, Gautschi O. Response to Pembrolizumab in a Patient with Relapsing Thymoma. J Thorac Oncol 2016; 11:e147-e149. [PMID: 27498287 DOI: 10.1016/j.jtho.2016.07.018] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2016] [Revised: 07/14/2016] [Accepted: 07/16/2016] [Indexed: 12/14/2022]
Affiliation(s)
- Thilo Zander
- Department of Medical Oncology, Cantonal Hospital Lucerne, Lucerne, Switzerland.
| | - Stefan Aebi
- Department of Medical Oncology, Cantonal Hospital Lucerne, Lucerne, Switzerland
| | | | - Andrea Zander
- Department of Radiology, Cantonal Hospital Lucerne, Lucerne, Switzerland
| | - Ralph Winterhalder
- Department of Medical Oncology, Cantonal Hospital Lucerne, Lucerne, Switzerland
| | - Christoph Brand
- Department of Dermatology, Cantonal Hospital Lucerne, Lucerne, Switzerland
| | - Joachim Diebold
- Department of Pathology, Cantonal Hospital Lucerne, Lucerne, Switzerland
| | - Oliver Gautschi
- Department of Medical Oncology, Cantonal Hospital Lucerne, Lucerne, Switzerland
| |
Collapse
|
32
|
Matter-Walstra K, Schwenkglenks M, Aebi S, Dedes K, Diebold J, Pietrini M, Klingbiel D, von Moos R, Gautschi O. A Cost-Effectiveness Analysis of Nivolumab versus Docetaxel for Advanced Nonsquamous NSCLC Including PD-L1 Testing. J Thorac Oncol 2016; 11:1846-1855. [PMID: 27311996 DOI: 10.1016/j.jtho.2016.05.032] [Citation(s) in RCA: 73] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2016] [Revised: 05/24/2016] [Accepted: 05/24/2016] [Indexed: 11/25/2022]
Abstract
INTRODUCTION Nivolumab (NIV) was recently approved in several countries for patients with pretreated advanced NSCLC. NIV is not cost-effective compared with docetaxel (DOC) for the treatment of squamous NSCLC. However, its cost-effectiveness for nonsquamous NSCLC and the consequences of programmed death ligand 1 (PD-L1) testing are unknown. METHODS This literature-based health economic study used CheckMate-057 trial data to model the incremental cost-effectiveness ratio (ICER) of NIV versus DOC in the Swiss health care setting. The effect of PD-L1 positivity for patient selection was assessed. RESULTS In the base case model, NIV (mean cost CHF66,208; mean effect 0.69 quality-adjusted life-years [QALYs]) compared with DOC (mean cost CHF37,618; mean effect 0.53 QALYs) resulted in an ICER of CHF177,478/QALY gained. Treating only patients with PD-L1-positive tumors (threshold ≥10%) with NIV compared with treating all patients with DOC produced a base case ICER of CHF124,891/QALY gained. Reduced drug price, dose, or treatment duration decreased the ICER partly below a willingness-to-pay threshold of CHF100,000/QALY. Health state utilities strongly influenced cost-effectiveness. CONCLUSIONS Compared with DOC, NIV is not cost-effective for the treatment of nonsquamous NSCLC at current prices in the Swiss health care setting. Price reduction or PD-L1 testing and selection of patients for NIV on the basis of test positivity improves cost-effectiveness compared with DOC.
Collapse
Affiliation(s)
- Klazien Matter-Walstra
- Swiss Group for Clinical Cancer Research Coordinating Centre, Bern, Switzerland; Institute of Pharmaceutical Medicine, University of Basel, Basel, Switzerland.
| | | | - Stefan Aebi
- Swiss Group for Clinical Cancer Research Coordinating Centre, Bern, Switzerland; Medical Oncology, Department of Internal Medicine, Cantonal Hospital Lucerne, Lucerne, Switzerland
| | - Konstantin Dedes
- Department of Gynaecology, University Hospital Zürich, Zürich, Switzerland
| | - Joachim Diebold
- Institute of Pathology, Cantonal Hospital Lucerne, Spitalstrasse, CH-6000 Lucerne, Switzerland
| | - Mario Pietrini
- Medical Controlling, Cantonal Hospital Lucerne, Lucerne, Switzerland
| | - Dirk Klingbiel
- Swiss Group for Clinical Cancer Research Coordinating Centre, Bern, Switzerland
| | - Roger von Moos
- Swiss Group for Clinical Cancer Research Coordinating Centre, Bern, Switzerland; Medical Oncology, Cantonal Hospital Graubünden, Chur, Switzerland
| | - Oliver Gautschi
- Swiss Group for Clinical Cancer Research Coordinating Centre, Bern, Switzerland; Medical Oncology, Department of Internal Medicine, Cantonal Hospital Lucerne, Lucerne, Switzerland
| | | |
Collapse
|
33
|
Alsalaheen B, Haines J, Yorke A, Diebold J. King-Devick Test reference values and associations with balance measures in high school American football players. Scand J Med Sci Sports 2015; 26:235-9. [PMID: 26648587 DOI: 10.1111/sms.12628] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 10/28/2015] [Indexed: 11/30/2022]
Abstract
The King-Devick test appears to be a promising tool in screening for concussions. However, limited evidence exists on the baseline associations between the K-D test and age and baseline screening tools used after concussion. Additionally, there are no published reference values for the K-D test in high school football players. The K-D test, the Balance Error Scoring System, and the Limits of Stability (LOS) test were administered to 157 high school football players. Additionally, a subsample of 62 participants completed the test twice to examine the reliability of K-D test. There was no relationship between the K-D test and the BESS, or the reaction time and directional control of LOS test. Students aged between 16 and 18 years demonstrated faster K-D test performance compared to students between 13 and 15 years of age. However, there was no association between K-D test and history of concussion. The reliability of the K-D test was (ICC2,1 = 0.89), and the minimal detectable change was 6.10 s. Normative reference values for high school football players are presented in this study.
Collapse
Affiliation(s)
- B. Alsalaheen
- Department of Physical Therapy; University of Michigan-Flint; Flint MI USA
| | - J. Haines
- Department of Physical Therapy; University of Michigan-Flint; Flint MI USA
| | - A. Yorke
- Department of Physical Therapy; University of Michigan-Flint; Flint MI USA
| | - J. Diebold
- Department of Physical Therapy; University of Michigan-Flint; Flint MI USA
| |
Collapse
|
34
|
Gautschi O, Stadelmann C, Aebersold-Keller F, König K, Büttner R, Heukamp LC, Betticher D, Baumann C, Buser K, Calderoni A, Casty A, DʼAddario G, Irlé C, Mamot C, Morant R, Trojan A, Pellicioli E, Jehle-Schwertfeger S, Aebi S, Diebold J. Mutation Profiling of Lung Cancers with Long-Term Response to Gefitinib Therapy. Oncol Res Treat 2015; 38:560-9. [DOI: 10.1159/000441367] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2015] [Accepted: 10/01/2015] [Indexed: 11/19/2022]
|
35
|
Jharap B, van Asseldonk DP, de Boer NKH, Bedossa P, Diebold J, Jonker AM, Leteurtre E, Verheij J, Wendum D, Wrba F, Zondervan PE, Colombel JF, Reinisch W, Mulder CJJ, Bloemena E, van Bodegraven AA. Diagnosing Nodular Regenerative Hyperplasia of the Liver Is Thwarted by Low Interobserver Agreement. PLoS One 2015; 10:e0120299. [PMID: 26054009 PMCID: PMC4459699 DOI: 10.1371/journal.pone.0120299] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2014] [Accepted: 01/28/2015] [Indexed: 12/17/2022] Open
Abstract
Background and Aims Nodular regenerative hyperplasia (NRH) of the liver is associated with several diseases and drugs. Clinical symptoms of NRH may vary from absence of symptoms to full-blown (non-cirrhotic) portal hypertension. However, diagnosing NRH is challenging. The objective of this study was to determine inter- and intraobserver agreement on the histopathologic diagnosis of NRH. Methods Liver specimens (n=48) previously diagnosed as NRH, were reviewed for the presence of NRH by seven pathologists without prior knowledge of the original diagnosis or clinical background. The majority of the liver specimens were from thiopurine using inflammatory bowel disease patients. Histopathologic features contributing to NRH were also assessed. Criteria for NRH were modified by consensus and subsequently validated. Interobserver agreement was evaluated by using the standard kappa index. Results After review, definite NRH, inconclusive NRH and no NRH were found in 35% (23-40%), 21% (13-27%) and 44% (38-56%), respectively (median, IQR). The median interobserver agreement for NRH was poor (κ = 0.20, IQR 0.14-0.28). The intraobserver variability on NRH ranged between 14% and 71%. After modification of the criteria and exclusion of biopsies with technical shortcomings, the interobserver agreement on the diagnosis NRH was fair (κ = 0.45). Conclusions The interobserver agreement on the histopathologic diagnosis of NRH was poor, even when assessed by well-experienced liver pathologists. Modification of the criteria of NRH based on consensus effort and exclusion of biopsies of poor quality led to a fairly increased interobserver agreement. The main conclusion of this study is that NRH is a clinicopathologic diagnosis that cannot reliably be based on histopathology alone.
Collapse
Affiliation(s)
- Bindia Jharap
- Department of Gastroenterology and Hepatology, VU University Medical Center, Amsterdam, the Netherlands
- * E-mail:
| | - Dirk P. van Asseldonk
- Department of Gastroenterology and Hepatology, VU University Medical Center, Amsterdam, the Netherlands
| | - Nanne K. H. de Boer
- Department of Gastroenterology and Hepatology, VU University Medical Center, Amsterdam, the Netherlands
| | - Pierre Bedossa
- Department of Pathology, Beaujon Hospital, Paris, France
| | - Joachim Diebold
- Department of Pathology, Cantonal Hospital, Lucerne, Switzerland
| | - A. Mieke Jonker
- Department of Pathology, Refaja Hospital, Stadskanaal, the Netherlands
| | | | - Joanne Verheij
- Department of Pathology, Academic Medical Center, Amsterdam, the Netherlands
| | | | - Fritz Wrba
- Department of Pathology, University Medical Center Vienna, Vienna, Austria
| | | | - Jean-Frédéric Colombel
- Department of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America
| | - Walter Reinisch
- Department of Gastroenterology and Hepatology, University Medical Center Vienna, Vienna, Austria
| | - Chris J. J. Mulder
- Department of Gastroenterology and Hepatology, VU University Medical Center, Amsterdam, the Netherlands
| | - Elisabeth Bloemena
- Department of Pathology, VU University Medical Center, Amsterdam, the Netherlands
| | - Adriaan A. van Bodegraven
- Department of Gastroenterology and Hepatology, VU University Medical Center, Amsterdam, the Netherlands
- Department of Internal Medicine, Gastroenterology and Geriatrics, ORBIS Medical Center, Sittard-Geleen, the Netherlands
| | | |
Collapse
|
36
|
Savic S, Diebold J, Zimmermann AK, Jochum W, Baschiera B, Grieshaber S, Tornillo L, Bisig B, Kerr K, Bubendorf L. Screening for ALK in non-small cell lung carcinomas: 5A4 and D5F3 antibodies perform equally well, but combined use with FISH is recommended. Lung Cancer 2015; 89:104-9. [PMID: 26056079 DOI: 10.1016/j.lungcan.2015.05.012] [Citation(s) in RCA: 54] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2015] [Revised: 05/12/2015] [Accepted: 05/13/2015] [Indexed: 02/07/2023]
Abstract
OBJECTIVES Immunohistochemistry (IHC) has become a promising method for pre-screening ALK-rearrangements in non-small cell lung carcinomas (NSCLC). Various ALK antibodies, detection systems and automated immunostainers are available. We therefore aimed to compare the performance of the monoclonal 5A4 (Novocastra, Leica) and D5F3 (Cell Signaling, Ventana) antibodies using two different immunostainers. Additionally we analyzed the accuracy of prospective ALK IHC-testing in routine diagnostics. MATERIALS AND METHODS Seventy-two NSCLC with available ALK FISH results and enriched for FISH-positive carcinomas were retrospectively analyzed. IHC was performed on BenchMarkXT (Ventana) using 5A4 and D5F3, respectively, and additionally with 5A4 on Bond-MAX (Leica). Data from our routine diagnostics on prospective ALK-testing with parallel IHC, using 5A4, and FISH were available from 303 NSCLC. RESULTS All three IHC protocols showed congruent results. Only 1/25 FISH-positive NSCLC (4%) was false negative by IHC. For all three IHC protocols the sensitivity, specificity, positive (PPV) and negative predictive values (NPV) compared to FISH were 96%, 100%, 100% and 97.8%, respectively. In the prospective cohort 3/32 FISH-positive (9.4%) and 2/271 FISH-negative (0.7%) NSCLC were false negative and false positive by IHC, respectively. In routine diagnostics the sensitivity, specificity, PPV and NPV of IHC compared to FISH were 90.6%, 99.3%, 93.5% and 98.9%, respectively. CONCLUSIONS 5A4 and D5F3 are equally well suited for detecting ALK-rearranged NSCLC. BenchMark and BOND-MAX immunostainers can be used for IHC with 5A4. True discrepancies between IHC and FISH results do exist and need to be addressed when implementing IHC in an ALK-testing algorithm.
Collapse
Affiliation(s)
- Spasenija Savic
- Institute of Pathology, University Hospital Basel, Schoenbeinstrasse 40, 4031 Basel, Switzerland.
| | - Joachim Diebold
- Institute of Pathology, Cantonal Hospital Lucerne, 6000 Luzern 16, Lucerne, Switzerland.
| | - Anne-Katrin Zimmermann
- Institute of Surgical Pathology, University Hospital Zurich, Schmelzbergstrasse 12, 8091 Zurich, Switzerland.
| | - Wolfram Jochum
- Institute of Pathology, Cantonal Hospital St. Gallen, Rorschacher Strasse 95, 9007 St. Gallen, Switzerland.
| | - Betty Baschiera
- Institute of Pathology, University Hospital Basel, Schoenbeinstrasse 40, 4031 Basel, Switzerland.
| | - Susanne Grieshaber
- Institute of Pathology, University Hospital Basel, Schoenbeinstrasse 40, 4031 Basel, Switzerland.
| | - Luigi Tornillo
- Institute of Pathology, University Hospital Basel, Schoenbeinstrasse 40, 4031 Basel, Switzerland.
| | - Bettina Bisig
- Institute of Pathology, University Hospital Lausanne, Rue du Bugnon 25, 1011 Lausanne, Switzerland.
| | - Keith Kerr
- Department of Pathology, Aberdeen Royal Infirmary, Foresterhill, Aberdeen AB25 2ZD, UK.
| | - Lukas Bubendorf
- Institute of Pathology, University Hospital Basel, Schoenbeinstrasse 40, 4031 Basel, Switzerland.
| |
Collapse
|
37
|
Mazières J, Zalcman G, Crinò L, Biondani P, Barlesi F, Filleron T, Dingemans AMC, Léna H, Monnet I, Rothschild SI, Cappuzzo F, Besse B, Thiberville L, Rouvière D, Dziadziuszko R, Smit EF, Wolf J, Spirig C, Pecuchet N, Leenders F, Heuckmann JM, Diebold J, Milia JD, Thomas RK, Gautschi O. Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort. J Clin Oncol 2015; 33:992-9. [PMID: 25667280 DOI: 10.1200/jco.2014.58.3302] [Citation(s) in RCA: 265] [Impact Index Per Article: 29.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
PURPOSE Approximately 1% of lung adenocarcinomas are driven by oncogenic ROS1 rearrangement. Crizotinib is a potent inhibitor of both ROS1 and ALK kinase domains. PATIENTS AND METHODS In the absence of a prospective clinical trial in Europe, we conducted a retrospective study in centers that tested for ROS1 rearrangement. Eligible patients had stage IV lung adenocarcinoma, had ROS1 rearrangement according to fluorescent in situ hybridization, and had received crizotinib therapy through an individual off-label use. Best response was assessed locally using RECIST (version 1.1). All other data were analyzed centrally. RESULTS We identified 32 eligible patients. One patient was excluded because next-generation sequencing was negative for ROS1 fusion. Median age was 50.5 years, 64.5% of patients were women, and 67.7% were never-smokers. Thirty patients were evaluable for progression-free survival (PFS), and 29 patients were evaluable for best response. We observed four patients with disease progression, two patients with stable disease, and objective response in 24 patients, including five complete responses (overall response rate, 80%; disease control rate, 86.7%). Median PFS was 9.1 months, and the PFS rate at 12 months was 44%. No unexpected adverse effects were observed. Twenty-six patients received pemetrexed (either alone or in combination with platinum and either before or after crizotinib) and had a response rate of 57.7% and a median PFS of 7.2 months. CONCLUSION Crizotinib was highly active at treating lung cancer in patients with a ROS1 rearrangement, suggesting that patients with lung adenocarcinomas should be tested for ROS1. Prospective clinical trials with crizotinib and other ROS1 inhibitors are ongoing or planned.
Collapse
Affiliation(s)
- Julien Mazières
- Julien Mazières, Damien Rouvière, and Julie D. Milia, Hôpital Larrey, Centre Hospitalier Universitaire, Université Paul Sabatier; Thomas Filleron, Institut Universitaire du Cancer, Toulouse; Gérard Zalcman, Centre Hospitalier Universitaire, Université de Caen-Basse Normandie, Caen; Pamela Biondani and Benjamin Besse, Gustave Roussy, Villejuif; Fabrice Barlesi, Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille; Hervé Léna, Centre Hospitalier Universitaire, Rennes; Isabelle Monnet, Centre Hospitalier Intercommunal de Créteil, Créteil; Luc Thiberville, Centre Hospitalier Universitaire, Rouen; Nicolas Pecuchet, Institut Curie, Paris, France; Lucio Crinò, Medica-Azienda Ospedaliera, Perugia; Federico Cappuzzo, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy; Anne-Marie C. Dingemans, Maastricht University Medical Center, Maastricht; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Sacha I. Rothschild, University Hospital Basel, Medical Oncology, Basel; Christian Spirig, Klinik St Anna; Joachim Diebold and Oliver Gautschi, Cantonal Hospital Luzern, Lucerne, Switzerland; Rafal Dziadziuszko, Gdansk Medical University, Gdansk, Poland; Jurgen Wolf and Roman K. Thomas, Center of Integrated Oncology Köln-Bonn, University Hospital Cologne, University of Cologne; Frauke Leenders and Roman K. Thomas, University of Cologne; Johannes M. Heuckmann, Blackfield AG, Cologne, Germany.
| | - Gérard Zalcman
- Julien Mazières, Damien Rouvière, and Julie D. Milia, Hôpital Larrey, Centre Hospitalier Universitaire, Université Paul Sabatier; Thomas Filleron, Institut Universitaire du Cancer, Toulouse; Gérard Zalcman, Centre Hospitalier Universitaire, Université de Caen-Basse Normandie, Caen; Pamela Biondani and Benjamin Besse, Gustave Roussy, Villejuif; Fabrice Barlesi, Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille; Hervé Léna, Centre Hospitalier Universitaire, Rennes; Isabelle Monnet, Centre Hospitalier Intercommunal de Créteil, Créteil; Luc Thiberville, Centre Hospitalier Universitaire, Rouen; Nicolas Pecuchet, Institut Curie, Paris, France; Lucio Crinò, Medica-Azienda Ospedaliera, Perugia; Federico Cappuzzo, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy; Anne-Marie C. Dingemans, Maastricht University Medical Center, Maastricht; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Sacha I. Rothschild, University Hospital Basel, Medical Oncology, Basel; Christian Spirig, Klinik St Anna; Joachim Diebold and Oliver Gautschi, Cantonal Hospital Luzern, Lucerne, Switzerland; Rafal Dziadziuszko, Gdansk Medical University, Gdansk, Poland; Jurgen Wolf and Roman K. Thomas, Center of Integrated Oncology Köln-Bonn, University Hospital Cologne, University of Cologne; Frauke Leenders and Roman K. Thomas, University of Cologne; Johannes M. Heuckmann, Blackfield AG, Cologne, Germany
| | - Lucio Crinò
- Julien Mazières, Damien Rouvière, and Julie D. Milia, Hôpital Larrey, Centre Hospitalier Universitaire, Université Paul Sabatier; Thomas Filleron, Institut Universitaire du Cancer, Toulouse; Gérard Zalcman, Centre Hospitalier Universitaire, Université de Caen-Basse Normandie, Caen; Pamela Biondani and Benjamin Besse, Gustave Roussy, Villejuif; Fabrice Barlesi, Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille; Hervé Léna, Centre Hospitalier Universitaire, Rennes; Isabelle Monnet, Centre Hospitalier Intercommunal de Créteil, Créteil; Luc Thiberville, Centre Hospitalier Universitaire, Rouen; Nicolas Pecuchet, Institut Curie, Paris, France; Lucio Crinò, Medica-Azienda Ospedaliera, Perugia; Federico Cappuzzo, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy; Anne-Marie C. Dingemans, Maastricht University Medical Center, Maastricht; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Sacha I. Rothschild, University Hospital Basel, Medical Oncology, Basel; Christian Spirig, Klinik St Anna; Joachim Diebold and Oliver Gautschi, Cantonal Hospital Luzern, Lucerne, Switzerland; Rafal Dziadziuszko, Gdansk Medical University, Gdansk, Poland; Jurgen Wolf and Roman K. Thomas, Center of Integrated Oncology Köln-Bonn, University Hospital Cologne, University of Cologne; Frauke Leenders and Roman K. Thomas, University of Cologne; Johannes M. Heuckmann, Blackfield AG, Cologne, Germany
| | - Pamela Biondani
- Julien Mazières, Damien Rouvière, and Julie D. Milia, Hôpital Larrey, Centre Hospitalier Universitaire, Université Paul Sabatier; Thomas Filleron, Institut Universitaire du Cancer, Toulouse; Gérard Zalcman, Centre Hospitalier Universitaire, Université de Caen-Basse Normandie, Caen; Pamela Biondani and Benjamin Besse, Gustave Roussy, Villejuif; Fabrice Barlesi, Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille; Hervé Léna, Centre Hospitalier Universitaire, Rennes; Isabelle Monnet, Centre Hospitalier Intercommunal de Créteil, Créteil; Luc Thiberville, Centre Hospitalier Universitaire, Rouen; Nicolas Pecuchet, Institut Curie, Paris, France; Lucio Crinò, Medica-Azienda Ospedaliera, Perugia; Federico Cappuzzo, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy; Anne-Marie C. Dingemans, Maastricht University Medical Center, Maastricht; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Sacha I. Rothschild, University Hospital Basel, Medical Oncology, Basel; Christian Spirig, Klinik St Anna; Joachim Diebold and Oliver Gautschi, Cantonal Hospital Luzern, Lucerne, Switzerland; Rafal Dziadziuszko, Gdansk Medical University, Gdansk, Poland; Jurgen Wolf and Roman K. Thomas, Center of Integrated Oncology Köln-Bonn, University Hospital Cologne, University of Cologne; Frauke Leenders and Roman K. Thomas, University of Cologne; Johannes M. Heuckmann, Blackfield AG, Cologne, Germany
| | - Fabrice Barlesi
- Julien Mazières, Damien Rouvière, and Julie D. Milia, Hôpital Larrey, Centre Hospitalier Universitaire, Université Paul Sabatier; Thomas Filleron, Institut Universitaire du Cancer, Toulouse; Gérard Zalcman, Centre Hospitalier Universitaire, Université de Caen-Basse Normandie, Caen; Pamela Biondani and Benjamin Besse, Gustave Roussy, Villejuif; Fabrice Barlesi, Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille; Hervé Léna, Centre Hospitalier Universitaire, Rennes; Isabelle Monnet, Centre Hospitalier Intercommunal de Créteil, Créteil; Luc Thiberville, Centre Hospitalier Universitaire, Rouen; Nicolas Pecuchet, Institut Curie, Paris, France; Lucio Crinò, Medica-Azienda Ospedaliera, Perugia; Federico Cappuzzo, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy; Anne-Marie C. Dingemans, Maastricht University Medical Center, Maastricht; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Sacha I. Rothschild, University Hospital Basel, Medical Oncology, Basel; Christian Spirig, Klinik St Anna; Joachim Diebold and Oliver Gautschi, Cantonal Hospital Luzern, Lucerne, Switzerland; Rafal Dziadziuszko, Gdansk Medical University, Gdansk, Poland; Jurgen Wolf and Roman K. Thomas, Center of Integrated Oncology Köln-Bonn, University Hospital Cologne, University of Cologne; Frauke Leenders and Roman K. Thomas, University of Cologne; Johannes M. Heuckmann, Blackfield AG, Cologne, Germany
| | - Thomas Filleron
- Julien Mazières, Damien Rouvière, and Julie D. Milia, Hôpital Larrey, Centre Hospitalier Universitaire, Université Paul Sabatier; Thomas Filleron, Institut Universitaire du Cancer, Toulouse; Gérard Zalcman, Centre Hospitalier Universitaire, Université de Caen-Basse Normandie, Caen; Pamela Biondani and Benjamin Besse, Gustave Roussy, Villejuif; Fabrice Barlesi, Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille; Hervé Léna, Centre Hospitalier Universitaire, Rennes; Isabelle Monnet, Centre Hospitalier Intercommunal de Créteil, Créteil; Luc Thiberville, Centre Hospitalier Universitaire, Rouen; Nicolas Pecuchet, Institut Curie, Paris, France; Lucio Crinò, Medica-Azienda Ospedaliera, Perugia; Federico Cappuzzo, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy; Anne-Marie C. Dingemans, Maastricht University Medical Center, Maastricht; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Sacha I. Rothschild, University Hospital Basel, Medical Oncology, Basel; Christian Spirig, Klinik St Anna; Joachim Diebold and Oliver Gautschi, Cantonal Hospital Luzern, Lucerne, Switzerland; Rafal Dziadziuszko, Gdansk Medical University, Gdansk, Poland; Jurgen Wolf and Roman K. Thomas, Center of Integrated Oncology Köln-Bonn, University Hospital Cologne, University of Cologne; Frauke Leenders and Roman K. Thomas, University of Cologne; Johannes M. Heuckmann, Blackfield AG, Cologne, Germany
| | - Anne-Marie C Dingemans
- Julien Mazières, Damien Rouvière, and Julie D. Milia, Hôpital Larrey, Centre Hospitalier Universitaire, Université Paul Sabatier; Thomas Filleron, Institut Universitaire du Cancer, Toulouse; Gérard Zalcman, Centre Hospitalier Universitaire, Université de Caen-Basse Normandie, Caen; Pamela Biondani and Benjamin Besse, Gustave Roussy, Villejuif; Fabrice Barlesi, Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille; Hervé Léna, Centre Hospitalier Universitaire, Rennes; Isabelle Monnet, Centre Hospitalier Intercommunal de Créteil, Créteil; Luc Thiberville, Centre Hospitalier Universitaire, Rouen; Nicolas Pecuchet, Institut Curie, Paris, France; Lucio Crinò, Medica-Azienda Ospedaliera, Perugia; Federico Cappuzzo, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy; Anne-Marie C. Dingemans, Maastricht University Medical Center, Maastricht; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Sacha I. Rothschild, University Hospital Basel, Medical Oncology, Basel; Christian Spirig, Klinik St Anna; Joachim Diebold and Oliver Gautschi, Cantonal Hospital Luzern, Lucerne, Switzerland; Rafal Dziadziuszko, Gdansk Medical University, Gdansk, Poland; Jurgen Wolf and Roman K. Thomas, Center of Integrated Oncology Köln-Bonn, University Hospital Cologne, University of Cologne; Frauke Leenders and Roman K. Thomas, University of Cologne; Johannes M. Heuckmann, Blackfield AG, Cologne, Germany
| | - Hervé Léna
- Julien Mazières, Damien Rouvière, and Julie D. Milia, Hôpital Larrey, Centre Hospitalier Universitaire, Université Paul Sabatier; Thomas Filleron, Institut Universitaire du Cancer, Toulouse; Gérard Zalcman, Centre Hospitalier Universitaire, Université de Caen-Basse Normandie, Caen; Pamela Biondani and Benjamin Besse, Gustave Roussy, Villejuif; Fabrice Barlesi, Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille; Hervé Léna, Centre Hospitalier Universitaire, Rennes; Isabelle Monnet, Centre Hospitalier Intercommunal de Créteil, Créteil; Luc Thiberville, Centre Hospitalier Universitaire, Rouen; Nicolas Pecuchet, Institut Curie, Paris, France; Lucio Crinò, Medica-Azienda Ospedaliera, Perugia; Federico Cappuzzo, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy; Anne-Marie C. Dingemans, Maastricht University Medical Center, Maastricht; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Sacha I. Rothschild, University Hospital Basel, Medical Oncology, Basel; Christian Spirig, Klinik St Anna; Joachim Diebold and Oliver Gautschi, Cantonal Hospital Luzern, Lucerne, Switzerland; Rafal Dziadziuszko, Gdansk Medical University, Gdansk, Poland; Jurgen Wolf and Roman K. Thomas, Center of Integrated Oncology Köln-Bonn, University Hospital Cologne, University of Cologne; Frauke Leenders and Roman K. Thomas, University of Cologne; Johannes M. Heuckmann, Blackfield AG, Cologne, Germany
| | - Isabelle Monnet
- Julien Mazières, Damien Rouvière, and Julie D. Milia, Hôpital Larrey, Centre Hospitalier Universitaire, Université Paul Sabatier; Thomas Filleron, Institut Universitaire du Cancer, Toulouse; Gérard Zalcman, Centre Hospitalier Universitaire, Université de Caen-Basse Normandie, Caen; Pamela Biondani and Benjamin Besse, Gustave Roussy, Villejuif; Fabrice Barlesi, Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille; Hervé Léna, Centre Hospitalier Universitaire, Rennes; Isabelle Monnet, Centre Hospitalier Intercommunal de Créteil, Créteil; Luc Thiberville, Centre Hospitalier Universitaire, Rouen; Nicolas Pecuchet, Institut Curie, Paris, France; Lucio Crinò, Medica-Azienda Ospedaliera, Perugia; Federico Cappuzzo, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy; Anne-Marie C. Dingemans, Maastricht University Medical Center, Maastricht; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Sacha I. Rothschild, University Hospital Basel, Medical Oncology, Basel; Christian Spirig, Klinik St Anna; Joachim Diebold and Oliver Gautschi, Cantonal Hospital Luzern, Lucerne, Switzerland; Rafal Dziadziuszko, Gdansk Medical University, Gdansk, Poland; Jurgen Wolf and Roman K. Thomas, Center of Integrated Oncology Köln-Bonn, University Hospital Cologne, University of Cologne; Frauke Leenders and Roman K. Thomas, University of Cologne; Johannes M. Heuckmann, Blackfield AG, Cologne, Germany
| | - Sacha I Rothschild
- Julien Mazières, Damien Rouvière, and Julie D. Milia, Hôpital Larrey, Centre Hospitalier Universitaire, Université Paul Sabatier; Thomas Filleron, Institut Universitaire du Cancer, Toulouse; Gérard Zalcman, Centre Hospitalier Universitaire, Université de Caen-Basse Normandie, Caen; Pamela Biondani and Benjamin Besse, Gustave Roussy, Villejuif; Fabrice Barlesi, Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille; Hervé Léna, Centre Hospitalier Universitaire, Rennes; Isabelle Monnet, Centre Hospitalier Intercommunal de Créteil, Créteil; Luc Thiberville, Centre Hospitalier Universitaire, Rouen; Nicolas Pecuchet, Institut Curie, Paris, France; Lucio Crinò, Medica-Azienda Ospedaliera, Perugia; Federico Cappuzzo, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy; Anne-Marie C. Dingemans, Maastricht University Medical Center, Maastricht; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Sacha I. Rothschild, University Hospital Basel, Medical Oncology, Basel; Christian Spirig, Klinik St Anna; Joachim Diebold and Oliver Gautschi, Cantonal Hospital Luzern, Lucerne, Switzerland; Rafal Dziadziuszko, Gdansk Medical University, Gdansk, Poland; Jurgen Wolf and Roman K. Thomas, Center of Integrated Oncology Köln-Bonn, University Hospital Cologne, University of Cologne; Frauke Leenders and Roman K. Thomas, University of Cologne; Johannes M. Heuckmann, Blackfield AG, Cologne, Germany
| | - Federico Cappuzzo
- Julien Mazières, Damien Rouvière, and Julie D. Milia, Hôpital Larrey, Centre Hospitalier Universitaire, Université Paul Sabatier; Thomas Filleron, Institut Universitaire du Cancer, Toulouse; Gérard Zalcman, Centre Hospitalier Universitaire, Université de Caen-Basse Normandie, Caen; Pamela Biondani and Benjamin Besse, Gustave Roussy, Villejuif; Fabrice Barlesi, Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille; Hervé Léna, Centre Hospitalier Universitaire, Rennes; Isabelle Monnet, Centre Hospitalier Intercommunal de Créteil, Créteil; Luc Thiberville, Centre Hospitalier Universitaire, Rouen; Nicolas Pecuchet, Institut Curie, Paris, France; Lucio Crinò, Medica-Azienda Ospedaliera, Perugia; Federico Cappuzzo, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy; Anne-Marie C. Dingemans, Maastricht University Medical Center, Maastricht; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Sacha I. Rothschild, University Hospital Basel, Medical Oncology, Basel; Christian Spirig, Klinik St Anna; Joachim Diebold and Oliver Gautschi, Cantonal Hospital Luzern, Lucerne, Switzerland; Rafal Dziadziuszko, Gdansk Medical University, Gdansk, Poland; Jurgen Wolf and Roman K. Thomas, Center of Integrated Oncology Köln-Bonn, University Hospital Cologne, University of Cologne; Frauke Leenders and Roman K. Thomas, University of Cologne; Johannes M. Heuckmann, Blackfield AG, Cologne, Germany
| | - Benjamin Besse
- Julien Mazières, Damien Rouvière, and Julie D. Milia, Hôpital Larrey, Centre Hospitalier Universitaire, Université Paul Sabatier; Thomas Filleron, Institut Universitaire du Cancer, Toulouse; Gérard Zalcman, Centre Hospitalier Universitaire, Université de Caen-Basse Normandie, Caen; Pamela Biondani and Benjamin Besse, Gustave Roussy, Villejuif; Fabrice Barlesi, Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille; Hervé Léna, Centre Hospitalier Universitaire, Rennes; Isabelle Monnet, Centre Hospitalier Intercommunal de Créteil, Créteil; Luc Thiberville, Centre Hospitalier Universitaire, Rouen; Nicolas Pecuchet, Institut Curie, Paris, France; Lucio Crinò, Medica-Azienda Ospedaliera, Perugia; Federico Cappuzzo, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy; Anne-Marie C. Dingemans, Maastricht University Medical Center, Maastricht; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Sacha I. Rothschild, University Hospital Basel, Medical Oncology, Basel; Christian Spirig, Klinik St Anna; Joachim Diebold and Oliver Gautschi, Cantonal Hospital Luzern, Lucerne, Switzerland; Rafal Dziadziuszko, Gdansk Medical University, Gdansk, Poland; Jurgen Wolf and Roman K. Thomas, Center of Integrated Oncology Köln-Bonn, University Hospital Cologne, University of Cologne; Frauke Leenders and Roman K. Thomas, University of Cologne; Johannes M. Heuckmann, Blackfield AG, Cologne, Germany
| | - Luc Thiberville
- Julien Mazières, Damien Rouvière, and Julie D. Milia, Hôpital Larrey, Centre Hospitalier Universitaire, Université Paul Sabatier; Thomas Filleron, Institut Universitaire du Cancer, Toulouse; Gérard Zalcman, Centre Hospitalier Universitaire, Université de Caen-Basse Normandie, Caen; Pamela Biondani and Benjamin Besse, Gustave Roussy, Villejuif; Fabrice Barlesi, Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille; Hervé Léna, Centre Hospitalier Universitaire, Rennes; Isabelle Monnet, Centre Hospitalier Intercommunal de Créteil, Créteil; Luc Thiberville, Centre Hospitalier Universitaire, Rouen; Nicolas Pecuchet, Institut Curie, Paris, France; Lucio Crinò, Medica-Azienda Ospedaliera, Perugia; Federico Cappuzzo, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy; Anne-Marie C. Dingemans, Maastricht University Medical Center, Maastricht; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Sacha I. Rothschild, University Hospital Basel, Medical Oncology, Basel; Christian Spirig, Klinik St Anna; Joachim Diebold and Oliver Gautschi, Cantonal Hospital Luzern, Lucerne, Switzerland; Rafal Dziadziuszko, Gdansk Medical University, Gdansk, Poland; Jurgen Wolf and Roman K. Thomas, Center of Integrated Oncology Köln-Bonn, University Hospital Cologne, University of Cologne; Frauke Leenders and Roman K. Thomas, University of Cologne; Johannes M. Heuckmann, Blackfield AG, Cologne, Germany
| | - Damien Rouvière
- Julien Mazières, Damien Rouvière, and Julie D. Milia, Hôpital Larrey, Centre Hospitalier Universitaire, Université Paul Sabatier; Thomas Filleron, Institut Universitaire du Cancer, Toulouse; Gérard Zalcman, Centre Hospitalier Universitaire, Université de Caen-Basse Normandie, Caen; Pamela Biondani and Benjamin Besse, Gustave Roussy, Villejuif; Fabrice Barlesi, Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille; Hervé Léna, Centre Hospitalier Universitaire, Rennes; Isabelle Monnet, Centre Hospitalier Intercommunal de Créteil, Créteil; Luc Thiberville, Centre Hospitalier Universitaire, Rouen; Nicolas Pecuchet, Institut Curie, Paris, France; Lucio Crinò, Medica-Azienda Ospedaliera, Perugia; Federico Cappuzzo, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy; Anne-Marie C. Dingemans, Maastricht University Medical Center, Maastricht; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Sacha I. Rothschild, University Hospital Basel, Medical Oncology, Basel; Christian Spirig, Klinik St Anna; Joachim Diebold and Oliver Gautschi, Cantonal Hospital Luzern, Lucerne, Switzerland; Rafal Dziadziuszko, Gdansk Medical University, Gdansk, Poland; Jurgen Wolf and Roman K. Thomas, Center of Integrated Oncology Köln-Bonn, University Hospital Cologne, University of Cologne; Frauke Leenders and Roman K. Thomas, University of Cologne; Johannes M. Heuckmann, Blackfield AG, Cologne, Germany
| | - Rafal Dziadziuszko
- Julien Mazières, Damien Rouvière, and Julie D. Milia, Hôpital Larrey, Centre Hospitalier Universitaire, Université Paul Sabatier; Thomas Filleron, Institut Universitaire du Cancer, Toulouse; Gérard Zalcman, Centre Hospitalier Universitaire, Université de Caen-Basse Normandie, Caen; Pamela Biondani and Benjamin Besse, Gustave Roussy, Villejuif; Fabrice Barlesi, Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille; Hervé Léna, Centre Hospitalier Universitaire, Rennes; Isabelle Monnet, Centre Hospitalier Intercommunal de Créteil, Créteil; Luc Thiberville, Centre Hospitalier Universitaire, Rouen; Nicolas Pecuchet, Institut Curie, Paris, France; Lucio Crinò, Medica-Azienda Ospedaliera, Perugia; Federico Cappuzzo, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy; Anne-Marie C. Dingemans, Maastricht University Medical Center, Maastricht; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Sacha I. Rothschild, University Hospital Basel, Medical Oncology, Basel; Christian Spirig, Klinik St Anna; Joachim Diebold and Oliver Gautschi, Cantonal Hospital Luzern, Lucerne, Switzerland; Rafal Dziadziuszko, Gdansk Medical University, Gdansk, Poland; Jurgen Wolf and Roman K. Thomas, Center of Integrated Oncology Köln-Bonn, University Hospital Cologne, University of Cologne; Frauke Leenders and Roman K. Thomas, University of Cologne; Johannes M. Heuckmann, Blackfield AG, Cologne, Germany
| | - Egbert F Smit
- Julien Mazières, Damien Rouvière, and Julie D. Milia, Hôpital Larrey, Centre Hospitalier Universitaire, Université Paul Sabatier; Thomas Filleron, Institut Universitaire du Cancer, Toulouse; Gérard Zalcman, Centre Hospitalier Universitaire, Université de Caen-Basse Normandie, Caen; Pamela Biondani and Benjamin Besse, Gustave Roussy, Villejuif; Fabrice Barlesi, Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille; Hervé Léna, Centre Hospitalier Universitaire, Rennes; Isabelle Monnet, Centre Hospitalier Intercommunal de Créteil, Créteil; Luc Thiberville, Centre Hospitalier Universitaire, Rouen; Nicolas Pecuchet, Institut Curie, Paris, France; Lucio Crinò, Medica-Azienda Ospedaliera, Perugia; Federico Cappuzzo, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy; Anne-Marie C. Dingemans, Maastricht University Medical Center, Maastricht; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Sacha I. Rothschild, University Hospital Basel, Medical Oncology, Basel; Christian Spirig, Klinik St Anna; Joachim Diebold and Oliver Gautschi, Cantonal Hospital Luzern, Lucerne, Switzerland; Rafal Dziadziuszko, Gdansk Medical University, Gdansk, Poland; Jurgen Wolf and Roman K. Thomas, Center of Integrated Oncology Köln-Bonn, University Hospital Cologne, University of Cologne; Frauke Leenders and Roman K. Thomas, University of Cologne; Johannes M. Heuckmann, Blackfield AG, Cologne, Germany
| | - Jurgen Wolf
- Julien Mazières, Damien Rouvière, and Julie D. Milia, Hôpital Larrey, Centre Hospitalier Universitaire, Université Paul Sabatier; Thomas Filleron, Institut Universitaire du Cancer, Toulouse; Gérard Zalcman, Centre Hospitalier Universitaire, Université de Caen-Basse Normandie, Caen; Pamela Biondani and Benjamin Besse, Gustave Roussy, Villejuif; Fabrice Barlesi, Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille; Hervé Léna, Centre Hospitalier Universitaire, Rennes; Isabelle Monnet, Centre Hospitalier Intercommunal de Créteil, Créteil; Luc Thiberville, Centre Hospitalier Universitaire, Rouen; Nicolas Pecuchet, Institut Curie, Paris, France; Lucio Crinò, Medica-Azienda Ospedaliera, Perugia; Federico Cappuzzo, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy; Anne-Marie C. Dingemans, Maastricht University Medical Center, Maastricht; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Sacha I. Rothschild, University Hospital Basel, Medical Oncology, Basel; Christian Spirig, Klinik St Anna; Joachim Diebold and Oliver Gautschi, Cantonal Hospital Luzern, Lucerne, Switzerland; Rafal Dziadziuszko, Gdansk Medical University, Gdansk, Poland; Jurgen Wolf and Roman K. Thomas, Center of Integrated Oncology Köln-Bonn, University Hospital Cologne, University of Cologne; Frauke Leenders and Roman K. Thomas, University of Cologne; Johannes M. Heuckmann, Blackfield AG, Cologne, Germany
| | - Christian Spirig
- Julien Mazières, Damien Rouvière, and Julie D. Milia, Hôpital Larrey, Centre Hospitalier Universitaire, Université Paul Sabatier; Thomas Filleron, Institut Universitaire du Cancer, Toulouse; Gérard Zalcman, Centre Hospitalier Universitaire, Université de Caen-Basse Normandie, Caen; Pamela Biondani and Benjamin Besse, Gustave Roussy, Villejuif; Fabrice Barlesi, Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille; Hervé Léna, Centre Hospitalier Universitaire, Rennes; Isabelle Monnet, Centre Hospitalier Intercommunal de Créteil, Créteil; Luc Thiberville, Centre Hospitalier Universitaire, Rouen; Nicolas Pecuchet, Institut Curie, Paris, France; Lucio Crinò, Medica-Azienda Ospedaliera, Perugia; Federico Cappuzzo, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy; Anne-Marie C. Dingemans, Maastricht University Medical Center, Maastricht; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Sacha I. Rothschild, University Hospital Basel, Medical Oncology, Basel; Christian Spirig, Klinik St Anna; Joachim Diebold and Oliver Gautschi, Cantonal Hospital Luzern, Lucerne, Switzerland; Rafal Dziadziuszko, Gdansk Medical University, Gdansk, Poland; Jurgen Wolf and Roman K. Thomas, Center of Integrated Oncology Köln-Bonn, University Hospital Cologne, University of Cologne; Frauke Leenders and Roman K. Thomas, University of Cologne; Johannes M. Heuckmann, Blackfield AG, Cologne, Germany
| | - Nicolas Pecuchet
- Julien Mazières, Damien Rouvière, and Julie D. Milia, Hôpital Larrey, Centre Hospitalier Universitaire, Université Paul Sabatier; Thomas Filleron, Institut Universitaire du Cancer, Toulouse; Gérard Zalcman, Centre Hospitalier Universitaire, Université de Caen-Basse Normandie, Caen; Pamela Biondani and Benjamin Besse, Gustave Roussy, Villejuif; Fabrice Barlesi, Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille; Hervé Léna, Centre Hospitalier Universitaire, Rennes; Isabelle Monnet, Centre Hospitalier Intercommunal de Créteil, Créteil; Luc Thiberville, Centre Hospitalier Universitaire, Rouen; Nicolas Pecuchet, Institut Curie, Paris, France; Lucio Crinò, Medica-Azienda Ospedaliera, Perugia; Federico Cappuzzo, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy; Anne-Marie C. Dingemans, Maastricht University Medical Center, Maastricht; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Sacha I. Rothschild, University Hospital Basel, Medical Oncology, Basel; Christian Spirig, Klinik St Anna; Joachim Diebold and Oliver Gautschi, Cantonal Hospital Luzern, Lucerne, Switzerland; Rafal Dziadziuszko, Gdansk Medical University, Gdansk, Poland; Jurgen Wolf and Roman K. Thomas, Center of Integrated Oncology Köln-Bonn, University Hospital Cologne, University of Cologne; Frauke Leenders and Roman K. Thomas, University of Cologne; Johannes M. Heuckmann, Blackfield AG, Cologne, Germany
| | - Frauke Leenders
- Julien Mazières, Damien Rouvière, and Julie D. Milia, Hôpital Larrey, Centre Hospitalier Universitaire, Université Paul Sabatier; Thomas Filleron, Institut Universitaire du Cancer, Toulouse; Gérard Zalcman, Centre Hospitalier Universitaire, Université de Caen-Basse Normandie, Caen; Pamela Biondani and Benjamin Besse, Gustave Roussy, Villejuif; Fabrice Barlesi, Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille; Hervé Léna, Centre Hospitalier Universitaire, Rennes; Isabelle Monnet, Centre Hospitalier Intercommunal de Créteil, Créteil; Luc Thiberville, Centre Hospitalier Universitaire, Rouen; Nicolas Pecuchet, Institut Curie, Paris, France; Lucio Crinò, Medica-Azienda Ospedaliera, Perugia; Federico Cappuzzo, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy; Anne-Marie C. Dingemans, Maastricht University Medical Center, Maastricht; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Sacha I. Rothschild, University Hospital Basel, Medical Oncology, Basel; Christian Spirig, Klinik St Anna; Joachim Diebold and Oliver Gautschi, Cantonal Hospital Luzern, Lucerne, Switzerland; Rafal Dziadziuszko, Gdansk Medical University, Gdansk, Poland; Jurgen Wolf and Roman K. Thomas, Center of Integrated Oncology Köln-Bonn, University Hospital Cologne, University of Cologne; Frauke Leenders and Roman K. Thomas, University of Cologne; Johannes M. Heuckmann, Blackfield AG, Cologne, Germany
| | - Johannes M Heuckmann
- Julien Mazières, Damien Rouvière, and Julie D. Milia, Hôpital Larrey, Centre Hospitalier Universitaire, Université Paul Sabatier; Thomas Filleron, Institut Universitaire du Cancer, Toulouse; Gérard Zalcman, Centre Hospitalier Universitaire, Université de Caen-Basse Normandie, Caen; Pamela Biondani and Benjamin Besse, Gustave Roussy, Villejuif; Fabrice Barlesi, Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille; Hervé Léna, Centre Hospitalier Universitaire, Rennes; Isabelle Monnet, Centre Hospitalier Intercommunal de Créteil, Créteil; Luc Thiberville, Centre Hospitalier Universitaire, Rouen; Nicolas Pecuchet, Institut Curie, Paris, France; Lucio Crinò, Medica-Azienda Ospedaliera, Perugia; Federico Cappuzzo, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy; Anne-Marie C. Dingemans, Maastricht University Medical Center, Maastricht; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Sacha I. Rothschild, University Hospital Basel, Medical Oncology, Basel; Christian Spirig, Klinik St Anna; Joachim Diebold and Oliver Gautschi, Cantonal Hospital Luzern, Lucerne, Switzerland; Rafal Dziadziuszko, Gdansk Medical University, Gdansk, Poland; Jurgen Wolf and Roman K. Thomas, Center of Integrated Oncology Köln-Bonn, University Hospital Cologne, University of Cologne; Frauke Leenders and Roman K. Thomas, University of Cologne; Johannes M. Heuckmann, Blackfield AG, Cologne, Germany
| | - Joachim Diebold
- Julien Mazières, Damien Rouvière, and Julie D. Milia, Hôpital Larrey, Centre Hospitalier Universitaire, Université Paul Sabatier; Thomas Filleron, Institut Universitaire du Cancer, Toulouse; Gérard Zalcman, Centre Hospitalier Universitaire, Université de Caen-Basse Normandie, Caen; Pamela Biondani and Benjamin Besse, Gustave Roussy, Villejuif; Fabrice Barlesi, Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille; Hervé Léna, Centre Hospitalier Universitaire, Rennes; Isabelle Monnet, Centre Hospitalier Intercommunal de Créteil, Créteil; Luc Thiberville, Centre Hospitalier Universitaire, Rouen; Nicolas Pecuchet, Institut Curie, Paris, France; Lucio Crinò, Medica-Azienda Ospedaliera, Perugia; Federico Cappuzzo, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy; Anne-Marie C. Dingemans, Maastricht University Medical Center, Maastricht; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Sacha I. Rothschild, University Hospital Basel, Medical Oncology, Basel; Christian Spirig, Klinik St Anna; Joachim Diebold and Oliver Gautschi, Cantonal Hospital Luzern, Lucerne, Switzerland; Rafal Dziadziuszko, Gdansk Medical University, Gdansk, Poland; Jurgen Wolf and Roman K. Thomas, Center of Integrated Oncology Köln-Bonn, University Hospital Cologne, University of Cologne; Frauke Leenders and Roman K. Thomas, University of Cologne; Johannes M. Heuckmann, Blackfield AG, Cologne, Germany
| | - Julie D Milia
- Julien Mazières, Damien Rouvière, and Julie D. Milia, Hôpital Larrey, Centre Hospitalier Universitaire, Université Paul Sabatier; Thomas Filleron, Institut Universitaire du Cancer, Toulouse; Gérard Zalcman, Centre Hospitalier Universitaire, Université de Caen-Basse Normandie, Caen; Pamela Biondani and Benjamin Besse, Gustave Roussy, Villejuif; Fabrice Barlesi, Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille; Hervé Léna, Centre Hospitalier Universitaire, Rennes; Isabelle Monnet, Centre Hospitalier Intercommunal de Créteil, Créteil; Luc Thiberville, Centre Hospitalier Universitaire, Rouen; Nicolas Pecuchet, Institut Curie, Paris, France; Lucio Crinò, Medica-Azienda Ospedaliera, Perugia; Federico Cappuzzo, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy; Anne-Marie C. Dingemans, Maastricht University Medical Center, Maastricht; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Sacha I. Rothschild, University Hospital Basel, Medical Oncology, Basel; Christian Spirig, Klinik St Anna; Joachim Diebold and Oliver Gautschi, Cantonal Hospital Luzern, Lucerne, Switzerland; Rafal Dziadziuszko, Gdansk Medical University, Gdansk, Poland; Jurgen Wolf and Roman K. Thomas, Center of Integrated Oncology Köln-Bonn, University Hospital Cologne, University of Cologne; Frauke Leenders and Roman K. Thomas, University of Cologne; Johannes M. Heuckmann, Blackfield AG, Cologne, Germany
| | - Roman K Thomas
- Julien Mazières, Damien Rouvière, and Julie D. Milia, Hôpital Larrey, Centre Hospitalier Universitaire, Université Paul Sabatier; Thomas Filleron, Institut Universitaire du Cancer, Toulouse; Gérard Zalcman, Centre Hospitalier Universitaire, Université de Caen-Basse Normandie, Caen; Pamela Biondani and Benjamin Besse, Gustave Roussy, Villejuif; Fabrice Barlesi, Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille; Hervé Léna, Centre Hospitalier Universitaire, Rennes; Isabelle Monnet, Centre Hospitalier Intercommunal de Créteil, Créteil; Luc Thiberville, Centre Hospitalier Universitaire, Rouen; Nicolas Pecuchet, Institut Curie, Paris, France; Lucio Crinò, Medica-Azienda Ospedaliera, Perugia; Federico Cappuzzo, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy; Anne-Marie C. Dingemans, Maastricht University Medical Center, Maastricht; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Sacha I. Rothschild, University Hospital Basel, Medical Oncology, Basel; Christian Spirig, Klinik St Anna; Joachim Diebold and Oliver Gautschi, Cantonal Hospital Luzern, Lucerne, Switzerland; Rafal Dziadziuszko, Gdansk Medical University, Gdansk, Poland; Jurgen Wolf and Roman K. Thomas, Center of Integrated Oncology Köln-Bonn, University Hospital Cologne, University of Cologne; Frauke Leenders and Roman K. Thomas, University of Cologne; Johannes M. Heuckmann, Blackfield AG, Cologne, Germany
| | - Oliver Gautschi
- Julien Mazières, Damien Rouvière, and Julie D. Milia, Hôpital Larrey, Centre Hospitalier Universitaire, Université Paul Sabatier; Thomas Filleron, Institut Universitaire du Cancer, Toulouse; Gérard Zalcman, Centre Hospitalier Universitaire, Université de Caen-Basse Normandie, Caen; Pamela Biondani and Benjamin Besse, Gustave Roussy, Villejuif; Fabrice Barlesi, Aix-Marseille University, Assistance Publique Hôpitaux de Marseille, Marseille; Hervé Léna, Centre Hospitalier Universitaire, Rennes; Isabelle Monnet, Centre Hospitalier Intercommunal de Créteil, Créteil; Luc Thiberville, Centre Hospitalier Universitaire, Rouen; Nicolas Pecuchet, Institut Curie, Paris, France; Lucio Crinò, Medica-Azienda Ospedaliera, Perugia; Federico Cappuzzo, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy; Anne-Marie C. Dingemans, Maastricht University Medical Center, Maastricht; Egbert F. Smit, VU University Medical Center, Amsterdam, the Netherlands; Sacha I. Rothschild, University Hospital Basel, Medical Oncology, Basel; Christian Spirig, Klinik St Anna; Joachim Diebold and Oliver Gautschi, Cantonal Hospital Luzern, Lucerne, Switzerland; Rafal Dziadziuszko, Gdansk Medical University, Gdansk, Poland; Jurgen Wolf and Roman K. Thomas, Center of Integrated Oncology Köln-Bonn, University Hospital Cologne, University of Cologne; Frauke Leenders and Roman K. Thomas, University of Cologne; Johannes M. Heuckmann, Blackfield AG, Cologne, Germany
| |
Collapse
|
38
|
Hübener C, Bidlingmaier M, Wu Z, Diebold J, Delius M, Friese K, Strasburger CJ, Hasbargen U. Human placental growth hormone: a potential new biomarker in gestational trophoblastic disease. Gynecol Oncol 2014; 136:264-8. [PMID: 25448485 DOI: 10.1016/j.ygyno.2014.11.077] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2014] [Revised: 11/20/2014] [Accepted: 11/22/2014] [Indexed: 10/24/2022]
Abstract
OBJECTIVES Gestational trophoblastic disease (GTD) involves a spectrum of abnormal proliferations arising from the placental villous trophoblast. Although the incidence is low, a biomarker with short serum half-life would be a major clinical advance to monitor surgical and medical treatment reducing the socioeconomic burden of multiple control visits as well as patient's anxiety. Placental growth hormone (hGH-V) plays an important role in the regulation of normal placental growth and has shown angiogenic effects. We aimed to determine by immunohistochemistry (IHC) whether hGH-V is expressed in GTD and whether it can be detected in the patient's blood for potential monitoring of surgical or medical treatment procedures. METHODS Tissue and sera were collected from women undergoing treatment for GTD in a tertiary care university hospital. We evaluated partial and complete hydatidiform moles, invasive moles and choriocarcinoma, n=16. Trophoblast specimens were examined by a newly developed IHC set-up for hGH-V in addition to gross morphologic and histopathological examination. Serum samples were analyzed by a highly sensitive hGH-V specific immunoassay. RESULTS hGH-V was localized in all entities of GTD to the syncytiotrophoblast by immunohistochemistry. Serum hGH-V was detected for the first time in GTD and was present in a high percentage of all analyzed entities. CONCLUSIONS hGH-V can be detected in all entities of GTD by IHC as well as by serum analysis and may therefore serve as a novel biomarker for the disease. Its clinical utility in diagnosis of GTD and monitoring surgical or medical treatment needs to be determined in further studies.
Collapse
Affiliation(s)
- Christoph Hübener
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, Campus Großhadern, Marchioninistr. 15, 81377 München, Germany.
| | - Martin Bidlingmaier
- Endocrine Laboratory, Medizinische Klinik und Poliklinik IV, Klinikum der Universität München, Ziemssenstraße 1, 80336 München, Germany
| | - Zida Wu
- Klinik für Endokrinologie, Diabetes und Ernährungsmedizin, Charité Universitätsmedizin Berlin, Campus Mitte, Charitéplatz 1, 10117 Berlin, Germany
| | - Joachim Diebold
- Pathologisches Institut, Luzerner Kantonsspital, 6000 Luzern 16, Switzerland
| | - Maria Delius
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, Campus Großhadern, Marchioninistr. 15, 81377 München, Germany
| | - Klaus Friese
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, Campus Großhadern, Marchioninistr. 15, 81377 München, Germany
| | - Christian J Strasburger
- Klinik für Endokrinologie, Diabetes und Ernährungsmedizin, Charité Universitätsmedizin Berlin, Campus Mitte, Charitéplatz 1, 10117 Berlin, Germany
| | - Uwe Hasbargen
- Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Klinikum der Universität München, Campus Großhadern, Marchioninistr. 15, 81377 München, Germany
| |
Collapse
|
39
|
Mazières J, Zalcman G, Crinò L, Biondani P, Filleron T, Dingemans A, Lena H, Monnet I, Rothschild S, Cappuzzo F, Thiberville L, Barlesi F, Dziadziuszko R, Smit E, Wolf J, Spirig C, Pecuchet N, Diebold J, Milia J, Gautschi O. Crizotinib in Patients with Lung Cancer and Ros1 Fusion: Results from the European Cohort Euros1. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.77] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
40
|
Abstract
Zusammenfassung
Aufgrund verschiedener Muster molekularer Veränderungen wird heute von einem dualistischen Modell der serösen Tumoren ausgegangen, wobei seröse Borderlinetumoren (SBT) und seröse Low-grade-Karzinome (LGSC) auf der einen Seite von serösen High-grade-Karzinomen (HGSC) auf der anderen Seite unterschieden werden. Der klinische Verlauf und die Art der Therapie von SBT und LGSC hängen entscheidend davon, ob sie mit extraovariellen Manifestationen einhergehen. Sogenannte invasive Implants von SBT entsprechen morphologisch dem Bild eines LGSC. Für die Unterscheidung von LGSC und HGSC hat sich das M.D.-Anderson-Gradingsystem etabliert. HGSC weisen ein breites Spektrum an Wachstumsmustern auf, zu dem auch ein transitionalepithelähnlicher Typ gehört. Karzinosarkome sind ebenfalls als HGSC-Variante zu interpretieren. Die neue Theorie, nach der sich alle serösen Neoplasien des Ovars, Peritoneums und der Tube von den Tubenfimbrien ableiten, lässt die Bezeichnung „Ovarialkarzinom“ als nicht mehr angemessen erscheinen.
Collapse
|
41
|
Mazieres J, Zalcman G, Crino L, Biondani P, Besse B, Dingemans AMC, Lena H, Monnet I, Rothschild S, Cappuzzo F, Thiberville L, Rouvière D, Dziadziuszko R, Smit EF, Wolf J, Spirig C, Pécuchet N, Diebold J, Milia J, Gautschi O. Efficacy of crizotinib in ROS1-rearranged lung cancer: The European experience. J Clin Oncol 2014. [DOI: 10.1200/jco.2014.32.15_suppl.11035] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
| | | | | | - Pamela Biondani
- Gustave Roussy, Cancer Campus, Grand Paris, Villejuif, France
| | | | | | - Hervé Lena
- CHU de Rennes, Hôpital Pontchailloux, Rennes, France
| | | | | | | | | | | | - Rafal Dziadziuszko
- Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland
| | | | | | | | - Nicolas Pécuchet
- Hôpital Européen Georges Pompidou (HEGP), Assistance Publique Hôpitaux de Paris (APHP), Paris, France
| | | | - Julie Milia
- Hôpital Larrey, CHU Toulouse, Toulouse, France
| | - Oliver Gautschi
- Department of Medical Oncology, Luzerner Kantonsspital, Luzern, Switzerland
| |
Collapse
|
42
|
Huellner MW, Collen TD, Gut P, Winterhalder R, Pauli C, Diebold J, Seifert B, Strobel K, Veit-Haibach P. Multiparametric PET/CT-perfusion does not add significant additional information for initial staging in lung cancer compared with standard PET/CT. EJNMMI Res 2014; 4:6. [PMID: 24450990 PMCID: PMC3901766 DOI: 10.1186/2191-219x-4-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2013] [Accepted: 01/17/2014] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND The purpose of this study was to assess the relationship of CT-perfusion (CTP), 18F-FDG-PET/CT and histological parameters, and the possible added value of CTP to FDG-PET/CT in the initial staging of lung cancer. METHODS Fifty-four consecutive patients (median age 65 years, 15 females, 39 males) with suspected lung cancer were evaluated prospectively by CT-perfusion scan and 18F-FDG-PET/CT scan. Overall, 46 tumors were identified. CTP parameters blood flow (BF), blood volume (BV), and mean transit time (MTT) of the tumor tissue were calculated. Intratumoral microvessel density (MVD) was assessed quantitatively. Differences in CTP parameters concerning tumor type, location, PET positivity of lymph nodes, TNM status, and UICC stage were analyzed. Spearman correlation analyses between CTP and 18F-FDG-PET/CT parameters (SUVmax, SUVmean, PETvol, and TLG), MVD, tumor size, and tumor stage were performed. RESULTS The mean BF (mL/100 mL min-1), BV (mL/100 mL), and MTT (s) was 35.5, 8.4, and 14.2, respectively. The BF and BV were lower in tumors with PET-positive lymph nodes (p = 0.02). However, the CTP values were not significantly different among the N stages. The CTP values were not different, depending on tumor size and location. No significant correlation was found between CTP parameters and MVD. CONCLUSIONS Overall, the CTP information showed only little additional information for the initial staging compared with standard FDG-PET/CT. Low perfusion in lung tumors might possibly be associated with metabolically active regional lymph nodes. Apart from that, both CTP and 18F-FDG-PET/CT parameter sets may reflect different pathophysiological mechanisms in lung cancer.
Collapse
Affiliation(s)
- Martin W Huellner
- Department of Radiology and Nuclear Medicine, Lucerne Cantonal Hospital, Spitalstrasse 1, Lucerne CH-6004, Switzerland.
| | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Gautschi O, Zander T, Keller FA, Strobel K, Hirschmann A, Aebi S, Diebold J. A patient with lung adenocarcinoma and RET fusion treated with vandetanib. J Thorac Oncol 2013; 8:e43-4. [PMID: 23584301 DOI: 10.1097/jto.0b013e31828a4d07] [Citation(s) in RCA: 93] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Affiliation(s)
- Oliver Gautschi
- Department of Medical Oncology, Cantonal Hospital, Luzern, Switzerland.
| | | | | | | | | | | | | |
Collapse
|
44
|
Malchers F, Dietlein F, Schöttle J, Lu X, Nogova L, Albus K, Fernandez-Cuesta L, Heuckmann JM, Gautschi O, Diebold J, Plenker D, Gardizi M, Scheffler M, Bos M, Seidel D, Leenders F, Richters A, Peifer M, Florin A, Mainkar PS, Karre N, Chandrasekhar S, George J, Silling S, Rauh D, Zander T, Ullrich RT, Reinhardt HC, Ringeisen F, Büttner R, Heukamp LC, Wolf J, Thomas RK. Cell-autonomous and non-cell-autonomous mechanisms of transformation by amplified FGFR1 in lung cancer. Cancer Discov 2013; 4:246-57. [PMID: 24302556 DOI: 10.1158/2159-8290.cd-13-0323] [Citation(s) in RCA: 82] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
UNLABELLED The 8p12 locus (containing the FGFR1 tyrosine kinase gene) is frequently amplified in squamous cell lung cancer. However, it is currently unknown which of the 8p12-amplified tumors are also sensitive to fibroblast growth factor receptor (FGFR) inhibition. We found that, in contrast with other recurrent amplifications, the 8p12 region included multiple centers of amplification, suggesting marked genomic heterogeneity. FGFR1-amplified tumor cells were dependent on FGFR ligands in vitro and in vivo. Furthermore, ectopic expression of FGFR1 was oncogenic, which was enhanced by expression of MYC. We found that MYC was coexpressed in 40% of FGFR1-amplified tumors. Tumor cells coexpressing MYC were more sensitive to FGFR inhibition, suggesting that patients with FGFR1-amplified and MYC-overexpressing tumors may benefit from FGFR inhibitor therapy. Thus, both cell-autonomous and non-cell-autonomous mechanisms of transformation modulate FGFR dependency in FGFR1-amplified lung cancer, which may have implications for patient selection for treatment with FGFR inhibitors. SIGNIFICANCE Amplification of FGFR1 is one of the most frequent candidate targets in lung cancer. Here, we show that multiple factors affect the tumorigenic potential of FGFR1, thus providing clinical hypotheses for refinement of patient selection.
Collapse
Affiliation(s)
- Florian Malchers
- 1Department of Translational Genomics, University of Cologne; 2Max-Planck-Institute for Neurological Research; Institutes of 3Pathology and 4Virology, University of Cologne;5Department I of Internal Medicine and Center for Integrated Oncology, University Hospital of Cologne; 6Blackfield AG, Cologne; 7Technical University Dortmund, Dortmund, Germany; 8Medical Oncology and 9Institute of Pathology, Cantonal Hospital, Luzern; 10Novartis Pharma AG, Basel, Switzerland; and 11Division of Natural Products Chemistry, CSIR-Indian Institute of Chemical Technology, Tarnaka, Hyderabad, India
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Gautschi O, Peters S, Zoete V, Aebersold-Keller F, Strobel K, Schwizer B, Hirschmann A, Michielin O, Diebold J. Lung adenocarcinoma with BRAF G469L mutation refractory to vemurafenib. Lung Cancer 2013; 82:365-7. [DOI: 10.1016/j.lungcan.2013.08.012] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2013] [Revised: 08/02/2013] [Accepted: 08/07/2013] [Indexed: 10/26/2022]
|
46
|
Wagner U, Harter P, Hilpert F, Mahner S, Reuß A, du Bois A, Petru E, Meier W, Ortner P, König K, Lindel K, Grab D, Piso P, Ortmann O, Runnebaum I, Pfisterer J, Lüftner D, Frickhofen N, Grünwald F, Maier BO, Diebold J, Hauptmann S, Kommoss F, Emons G, Radeleff B, Gebhardt M, Arnold N, Calaminus G, Weisse I, Weis J, Sehouli J, Fink D, Burges A, Hasenburg A, Eggert C. S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013. Geburtshilfe Frauenheilkd 2013; 73:874-889. [PMID: 24771937 DOI: 10.1055/s-0033-1350713] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
|
47
|
Mazières J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, Besse B, Blons H, Mansuet-Lupo A, Urban T, Moro-Sibilot D, Dansin E, Chouaid C, Wislez M, Diebold J, Felip E, Rouquette I, Milia JD, Gautschi O. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives. J Clin Oncol 2013; 31:1997-2003. [PMID: 23610105 DOI: 10.1200/jco.2012.45.6095] [Citation(s) in RCA: 470] [Impact Index Per Article: 42.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
PURPOSE HER2 mutations are identified in approximately 2%of non-small-cell lung cancers (NSCLC). There are few data available that describe the clinical course of patients with HER2-mutated NSCLC. PATIENTS AND METHODS We retrospectively identified 65 NSCLC, diagnosed with a HER2 in-frame insertion in exon 20. We collected clinicopathologic characteristics, patients' outcomes, and treatments. RESULTS HER2 mutation was identified in 65 (1.7%) of 3,800 patients tested and was almost an exclusive driver, except for one single case with a concomitant KRAS mutation. Our population presented with a median age of 60 years (range, 31 to 86 years), a high proportion of women (45 women v 20 men; 69%), and a high proportion of never-smokers (n= 34; 52.3%). All tumors were adenocarcinomas and 50% were stage IV at diagnosis. For these latter cases, 22 anti-human epidermal growth factor receptor 2 (HER2) treatments were administered after conventional chemotherapy in 16 patients. Subsequently, four patients experienced progressive disease, seven experienced disease stabilizations, and 11 experienced partial responses (overall response rate, 50%; disease control rate [DCR], 82%). Specifically, we observed a DCR of 93% for trastuzumab-based therapies (n = 15) and a DCR of 100% for afatinib (n = 3) but no response to other HER2-targeted drugs (n = 3). Progression-free survival for patients with HER2 therapies was 5.1 months. Median survival was of 89.6 and 22.9 months for early-stage and stage IV patients, respectively. CONCLUSION This study, the largest to date dedicated to HER2-mutated NSCLC, reinforces the importance of screening for HER2 mutations in lung adenocarcinomas and suggests the potential efficacy of HER2-targeted drugs in this population.
Collapse
Affiliation(s)
- Julien Mazières
- Centre Hospitalier Universitaire de Toulouse, Université de Toulouse III, Toulouse Cedex, France.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Gautschi O, Schefer H, Riklin C, Strobel K, Diebold J. Experience in Integrating <i>ALK</i> Testing and Crizotinib into the Routine Treatment of Patients with Non-Small Cell Lung Cancer. Oncol Res Treat 2013; 36:342-347. [DOI: 10.1159/000351163] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/30/2023]
Abstract
<b><i>Background: </i></b>Crizotinib, an inhibitor of the anaplastic lymphoma kinase (ALK), is approved since 2012 in Switzerland for use in <i>ALK</i>-rearranged advanced pretreated non-small cell lung cancer (NSCLC). <b><i>Patients and Methods: </i></b>Here we describe our own experience with crizotinib and <i>ALK </i>testing via fluorescence in-situ hybridization (FISH) in the first 10 <i>ALK</i>-positive patients who were treated in central Switzerland in 2011 on a compassionate use basis. <b><i>Results: </i></b>We have demonstrated that FISH testing for <i>ALK </i>can be performed simultaneously with other diagnostic procedures, providing oncologists with results in a timely manner to make informed decisions about patient treatment. The majority of our patients treated with crizotinib had a clinical benefit, and the drug was tolerated well. <b><i>Conclusion: </i></b>The clinical development of crizotinib has been extremely rapid. Nonetheless, by the time crizotinib was approved, many centers including our own had local testing in place and clinical experience with the drug. This emphasizes the importance of broad clinical studies and compassionate use programs in oncology.
Collapse
|
49
|
Hirschmann A, Lamb TA, Marchal G, Padilla M, Diebold J. Simultaneous analysis of HER2 gene and protein on a single slide facilitates HER2 testing of breast and gastric carcinomas. Am J Clin Pathol 2012; 138:837-44. [PMID: 23161718 DOI: 10.1309/ajcpl5iv0lawserg] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Abstract
This study sought to evaluate a new combined gene and protein detection platform in the context of HER2 evaluation in breast and gastric carcinomas. HER2 immunohistochemistry (IHC) and dual color in situ hybridization (Dual ISH) were combined on a single slide. Results were compared with conventional HER2 IHC and fluorescence ISH. Results from the gene and protein assay were reliable and highly reproducible for both breast and gastric carcinomas. Concordance was found between conventional HER2 IHC and ISH testing and the gene and protein assay in the same laboratory (>95% for Dual ISH; lower for IHC because of different antibody clones), between IHC and Dual ISH performed on the same slide (>92%), and in the gene and protein assays between laboratories (>96%). This cost- and time-effective method provides fast and definitive results (IHC confirmed by means of Dual ISH) to aid in rapid treatment decisions. It can also be applied to other gene and protein combinations.
Collapse
|
50
|
Nielsen J, Diebold J, Walton T, Boyle M, Walt R. Converting Riparian Restoration Waste to Energy: Testing Tamarisk (Tamarix spp.) Woody Biomass as Fuel for Downdraft Gasification. ECOL RESTOR 2011. [DOI: 10.3368/er.29.3.270] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|